



Oncology Nutrition
for **Clinical Practice**
Second Edition

Oncology Nutrition Dietetic Practice Group
Editors: Anne Coble Voss, PhD, RDN, LDN, and
Valaree Williams, MS, RD, CSO, LDN, CNSC, FAND

Academy of Nutrition and Dietetics
120 S. Riverside Plaza, Suite 2190
Chicago, IL 60606

Oncology Nutrition for Clinical Practice, Second Edition

ISBN 978-0-88091-067-5 (print)

ISBN 978-0-88091-154-2 (eBook)

Catalog Number 527421 (print)

Catalog Number 527421e (eBook)

Copyright © 2021, Academy of Nutrition and Dietetics. All rights reserved. Except for brief quotations embodied in critical articles or reviews, no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. The Academy of Nutrition and Dietetics disclaims responsibility for the application of the information contained herein.

10 9 8 7 6 5 4 3 2

For more information on the Academy of Nutrition and Dietetics, visit www.eatright.org.

Library of Congress Cataloging-in-Publication Data

Names: Coble Voss, Anne, editor. | Williams, Valaree, editor. | Academy of Nutrition and Dietetics. Pediatric Nutrition Practice Group, publisher.

Title: Oncology nutrition for clinical practice / editors, Anne Coble Voss, PhD, RDN, LDN, and Valaree Williams, MS, RD, CSO, LDN, CNSC, FAND.

Description: Second edition. | Chicago : Academy of Nutrition and Dietetics, 2021. | Includes bibliographical references and index.

Identifiers: LCCN 2021007365 (print) | LCCN 2021007366 (ebook) | ISBN 9780880910675 (paperback) | ISBN 9780880911542 (ebook)

Subjects: LCSH: Cancer--Diet therapy. | Cancer--Patients--Nutrition.

Classification: LCC RC268.45 .O53 2021 (print) | LCC RC268.45 (ebook) | DDC 616.99/40654--dc23

LC record available at <https://lcn.loc.gov/2021007365>

LC ebook record available at <https://lcn.loc.gov/2021007366>

Oncology Nutrition *for* Clinical Practice

Second Edition

Oncology Nutrition Dietetic Practice Group

Editors: Anne Coble Voss, PhD, RDN, LDN, and

Valaree Williams, MS, RD, CSO, LDN, CNSC, FAND

Contents

vi Boxes, Tables, and Figures	36 <i>Chapter 3</i> Energy Balance, Body Composition, and Physical Activity for Cancer Prevention, Treatment, and Survivorship	126 <i>Chapter 8</i> Nutrition and Cancer Survivorship
xvi Contributors	58 <i>Chapter 4</i> Nutrition Risk Screening and Assessment of the Oncology Patient	156 <i>Chapter 9</i> Nutritional Effects of Cancer Treatment: Medical Oncology
xx Reviewers	74 <i>Chapter 5</i> Nutritional Needs of the Adult Oncology Patient	182 <i>Chapter 10</i> Nutritional Effects of Cancer Treatment: Radiation Oncology
xxii Preface	88 <i>Chapter 6</i> Integrative Oncology: The Role of Mind-Body Interventions and Practices in Cancer	194 <i>Chapter 11</i> Managing Nutrition Impact Symptoms of Cancer Treatment
xxiv About the Editors and the Oncology Nutrition Dietetic Practice Group	110 <i>Chapter 7</i> Diets, Functional Foods, and Dietary Supplements for Cancer Prevention and Survival	218 <i>Chapter 12</i> Nutrition Support in the Oncology Setting
1 <i>Chapter 1</i> Overview of Cancer, Carcinogenesis, and the Role of Nutrition		250 <i>Chapter 13</i> Nutrition Management of the Pediatric Oncology Patient
12 <i>Chapter 2</i> Nutrition and Cancer Prevention		

278

Chapter 14

Medical Nutrition
Therapy for Hematologic
Malignancies

304

Chapter 15

Medical Nutrition Therapy
for Hematopoietic Cell
Transplantation

330

Chapter 16

Medical Nutrition Therapy
for Primary Brain Tumors

346

Chapter 17

Medical Nutrition Therapy
for Breast Cancer

374

Chapter 18

Medical Nutrition Therapy
for Esophageal and Gastric
Cancers

404

Chapter 19

Medical Nutrition Therapy
for Cancers of the Liver,
Bile Duct, Gallbladder,
Small Bowel, Colon, Rectum,
and Anus

434

Chapter 20

Medical Nutrition Therapy
for Pancreatic Cancer

472

Chapter 21

Medical Nutrition Therapy
for Head and Neck Cancers

486

Chapter 22

Medical Nutrition Therapy
for Lung Cancer

498

Chapter 23

Medical Nutrition Therapy
for Gynecologic Cancers

514

Chapter 24

Medical Nutrition Therapy
for Prostate Cancer

530

Chapter 25

Medical Nutrition Therapy
for Thyroid Cancer

544

Chapter 26

Nutrition Management
of Oncology Patients in
Palliative and Hospice
Settings

562

Chapter 27

Medical Cannabis for Cancer
Symptom Management

578

Appendix A

Evidence-Based Guidelines
and Diets for Cancer
Prevention and Survival

596

Appendix B

Alternative and Unfounded
Diets and Therapies for
Cancer Prevention and
Treatment

614

Appendix C

Select Dietary Supplements
and Functional Foods

664

Continuing Professional
Education

666

Index



Boxes, Tables, and Figures



Boxes

- 1**
Box 1.1 The Five Most Common Types of New Cancer Cases in the United States
- 3**
Box 1.2 Summary of the Tumor, Lymph Node, Metastasis (TNM) Classification System
- 4**
Box 1.3 Tumor Grading System of the American Joint Committee on Cancer
- 8**
Box 1.4 Potential Nutrition-Related Concerns and Outcomes Across the Cancer Continuum
- 14**
Box 2.1 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations
- 16**
Box 2.2 Key Practice Points for Adiposity and Weight Gain
- 17**
Box 2.3 Key Practice Points for Physical Activity
- 18**
Box 2.4 Key Practice Points for a Predominately Plant-Based Diet
- 19**
Box 2.5 Key Practice Points for Foods That Promote Weight Gain
- 20**
Box 2.6 Key Practice Points for Red and Processed Meats
- 21**
Box 2.7 Key Practice Points for Sugar-Sweetened Beverages
- 22**
Box 2.8 Key Practice Points for Alcoholic Beverages
- 22**
Box 2.9 Key Practice Points for Dietary Supplements
- 23**
Box 2.10 Key Practice Points for Lactation and Breastfeeding
- 24**
Box 2.11 Key Practice Points for Cancer Survivors
- 41**
Box 3.1 Physical Activity Guidelines for Cancer Prevention and Cancer Survivorship
- 46**
Box 3.2 Types of Energy Restriction Dietary Patterns
- 48**
Box 3.3 Types and Characteristics of Weight-Management Programs Available to Cancer Survivors

62	<i>Box 4.1</i> Oncology-Related Nutrition Assessment (Based on the Five Domains of Nutrition Assessment as Part of the Nutrition Care Process)	98	<i>Box 6.3</i> Selected Yoga Lineages	172	<i>Box 9.4</i> Side Effects and Nutritional Implications of Monoclonal Antibodies
75	<i>Box 5.1</i> Effects of Systemic Inflammation on Macronutrient Metabolism	102	<i>Box 6.4</i> Mind-Body Intervention Resources	174	<i>Box 9.5</i> Small-Molecule Drugs: Protein-Targeted Agents
80	<i>Box 5.2</i> General Medical Conditions and Cancer-Related Treatments Affecting Micronutrient Levels	115	<i>Box 7.1</i> Resources on Functional Foods	175	<i>Box 9.6</i> Small-Molecule Drugs: Angiogenesis Inhibitors
81	<i>Box 5.3</i> Energy Expenditure Terminology	120	<i>Box 7.2</i> Resources on Dietary Supplements	176	<i>Box 9.7</i> Nonspecific Immunotherapies
90	<i>Box 6.1</i> Selected Popular Mind-Body Interventions	128	<i>Box 8.1</i> Long-Term Nutrition-Related Side Effects and Interventions for Common Cancers	178	<i>Box 9.8</i> Hormonal Agents Used in Cancer Treatment
94	<i>Box 6.2</i> Evidence Grades Used by the Society for Integrative Oncology in Its Clinical Guidelines for the Use of Integrative Therapies With Breast Cancer	148	<i>Box 8.2</i> Nutrition Resources in Cancer Survivorship	187	<i>Box 10.1</i> Possible Late Side Effects of Site-Specific Radiation Therapy
		158	<i>Box 9.1</i> Cancer-Specific Factors Affecting Response to Cancer Treatment	188	<i>Box 10.2</i> Possible Side Effects of Total Body Irradiation
		159	<i>Box 9.2</i> Goals of Cancer Therapy Approaches	188	<i>Box 10.3</i> General Types of Brachytherapy Placement
		162	<i>Box 9.3</i> Possible Side Effects and Nutritional Implications of Chemotherapy Agents	189	<i>Box 10.4</i> Types of Brachytherapy by Duration

190 <i>Box 10.5</i> Possible Acute and Late-Occurring Side Effects of Brachytherapy	200 <i>Box 11.4</i> Constipation: Definition, Severity Grades, Considerations, and Interventions	212 <i>Box 11.10</i> Oral Mucositis and Esophagitis: Definition, Severity Grades, Considerations, and Interventions
192 <i>Box 10.6</i> Possible Side Effects of Radiopharmaceuticals for Metastatic Bone Pain	202 <i>Box 11.5</i> Diarrhea: Definition, Severity Grades, Considerations, and Interventions	214 <i>Box 11.11</i> Oral Candidiasis: Definition, Severity Grades, Considerations, and Interventions
196 <i>Box 11.1</i> The National Cancer Institute's Common Terminology Criteria for Adverse Events: Grading System for Severity of Adverse Events	204 <i>Box 11.6</i> Dysphagia: Definition, Severity Grades, Considerations, and Interventions	215 <i>Box 11.12</i> Xerostomia: Definition, Severity Grades, Considerations, and Interventions
196 <i>Box 11.2</i> Anorexia and Early Satiety: Definition, Severity Grades, Considerations, and Interventions	206 <i>Box 11.7</i> Fatigue: Definition, Severity Grades, Considerations, and Interventions	220 <i>Box 12.1</i> Oncology Specific Indications for Enteral Nutrition
198 <i>Box 11.3</i> Changes in Taste and Smell: Definition, Severity Grades, Considerations, and Interventions	208 <i>Box 11.8</i> Malabsorption: Definition, Severity Grades, Considerations, and Interventions	221 <i>Box 12.2</i> Enteral Access Devices and Considerations
	210 <i>Box 11.9</i> Nausea and Vomiting: Definition, Severity Grades, Considerations, and Interventions	223 <i>Box 12.3</i> Enteral Nutrition Formulations and Modular Nutrients
		226 <i>Box 12.4</i> Metabolic Complications and Potential Corrections During Enteral Nutrition Therapy

228

Box 12.5 Gastrointestinal Complications and Potential Corrections During Enteral Nutrition Therapy

230

Box 12.6 Recommendations for Managing Clogged EADs

231

Box 12.7 Common Enteral Nutrition-Related Medication Concerns

235

Box 12.8 Oncology-Specific Indications for Parenteral Nutrition

241

Box 12.9 Suggested Monitoring of Patients on Parenteral Nutrition

242

Box 12.10 Long-Term Complications From Parenteral Nutrition and Suggestions for Prevention and Management

253

Box 13.1 Childhood Cancer Resources

254

Box 13.2 Acute Lymphoblastic Leukemia: Treatment Phases, Chemotherapy, and Side Effects

255

Box 13.3 Categories of Central Nervous System Tumors and Nutritional Considerations

259

Box 13.4 Risk Factors for Malnutrition in Pediatric Patients With Cancer

263

Box 13.5 Recommended Assessment Parameters for Pediatric Oncology Patients

265

Box 13.6 Equations for Adjusting Body Weight for Amputations

267

Box 13.7 Holliday-Segar Equations for Estimating Fluid Needs in Pediatric Patients

269

Box 13.8 Appetite Stimulants Commonly Used in Pediatric Oncology

309

Box 15.1 Baseline Nutrition Assessment Before Hematopoietic Cell Transplantation

310

Box 15.2 Daily Nutrient Requirements During Hematopoietic Cell Transplantation

313

Box 15.3 Dietary Guidelines for Immunosuppressed Patients Following Hematopoietic Cell Transplantation

317

Box 15.4 Therapies for the Prevention and Treatment of Graft-Versus-Host Disease

319

Box 15.5 Dietary Progression for Gastrointestinal Symptoms in Graft-Versus-Host Disease

322

Box 15.6 Nutrition Impact Symptoms of Chronic Graft-Versus-Host Disease and Recommended Medical Nutrition Therapies

334

Box 16.1 Nutrition Impact Symptoms Associated With Treatment Medications Used for Primary Brain Tumors

335

Box 16.2 Screening and Monitoring for the Ketogenic Diet

337

Box 16.3 Responsibilities for Implementation and Monitoring of the Ketogenic Diet

338

Box 16.4 Ketogenic Diet: Resources for Professionals

338

Box 16.5 Managing Potential Side Effects of the Ketogenic Diet

341

Box 16.6 Recommendations for Caregivers of Patients With Primary Brain Tumor

341

Box 16.7 Mealtime Strategies for Patients With Primary Brain Tumors

347

Box 17.1 Modifiable and Nonmodifiable Risk Factors for Breast Cancer

350

Box 17.2 Endocrine, Targeted, and Maintenance Therapy for Breast Cancer Patients

361

Box 17.3 Evidence for Food and Lifestyle Advice for Patients With Breast Cancer

376

Box 18.1 Esophageal Cancer Prevalence and Risk Factors

376

Box 18.2 Common Esophageal Cancer Treatments and Related Nutrition Impact Symptoms

377

Box 18.3 Best-Practice Diet Recommendations for Patients With Esophageal Stents

381

Box 18.4 Dumping Syndrome

384

Box 18.5 Risk Factors for Gastric Cancer

387

Box 18.6 Evidence Regarding the Role of Nutrition Support in Gastric Cancer

390

Box 18.7 Postgastrectomy Syndromes

394

Box 18.8 Nutrient Deficiencies and Related Conditions After Partial or Total Gastrectomy

412

Box 19.1 Common Treatment-Related Nutrition Issues in Gastrointestinal Cancers and Recommended Interventions

416

Box 19.2 Estimated Nutritional Needs and Concerns in Patients With Hepatic Compromise and Recommended Interventions

436

Box 20.1 Pancreatic Cancer Statistics, United States

438

Box 20.2 Systemic Treatment Agents for Pancreatic Adenocarcinoma and Corresponding Nutrition Impact Symptoms

<p>441 <i>Box 20.3</i> Common Surgeries for Pancreatic and Periampullary Tumors, Resulting Anatomic Changes, and Associated Nutrition Impact Symptoms</p> <p>447 <i>Box 20.4</i> Common Symptoms at the Time of Diagnosis of Pancreatic or Periampullary Tumors</p> <p>448 <i>Box 20.5</i> Signs and Symptoms of Pancreatic Exocrine Insufficiency</p> <p>451 <i>Box 20.6</i> Resources for Financial Assistance for Pancreatic Enzyme Products</p> <p>459 <i>Box 20.7</i> Recommendations for Micronutrient Evaluation in Survivors of Pancreatic Cancer</p> <p>460 <i>Box 20.8</i> Recommendations for Micronutrient Replacement in Survivors of Pancreatic Cancer</p>	<p>473 <i>Box 21.1</i> Statistics for Oral Cavity and Pharynx Cancers, United States</p> <p>473 <i>Box 21.2</i> Risk Factors for Head and Neck Cancers</p> <p>474 <i>Box 21.3</i> Symptoms of Head and Neck Cancers</p> <p>476 <i>Box 21.4</i> Treatments for Head and Neck Cancers and Associated Nutrition Impact Symptoms</p> <p>477 <i>Box 21.5</i> Comprehensive Care for Head and Neck Cancers: Collaboration With the Radiation Oncology Team</p> <p>478 <i>Box 21.6</i> Comprehensive Care for Head and Neck Cancers: Collaboration With the Surgical Team</p> <p>481 <i>Box 21.7</i> Nutrition Interventions for Patients With Head and Neck Cancers</p>	<p>481 <i>Box 21.8</i> Counseling for Patients With Head and Neck Cancers and Their Caregivers</p> <p>482 <i>Box 21.9</i> Chronic Challenges for Head and Neck Cancer Survivors</p> <p>493 <i>Box 22.1</i> Identifying Patients With Lung Cancer Who Are at High Nutritional Risk</p> <p>501 <i>Box 23.1</i> Gynecologic Cancers: Risk Factors and Protective Factors</p> <p>515 <i>Box 24.1</i> Prostate Cancer in the United States, 2020</p> <p>517 <i>Box 24.2</i> Diet and Lifestyle Risk Factors and Prostate Cancer Risk</p> <p>518 <i>Box 24.3</i> Prostate Cancer Treatment Options and Possible Side Effects</p> <p>521 <i>Box 24.4</i> Medical Nutrition Therapy for Prostate Cancer Treatments</p>
--	--	--



Tables

68

Table 4.1 Clinical Characteristics That Support a Diagnosis of Malnutrition

77

Table 5.1 Protein Requirements in Health and Disease

78

Table 5.2 Acceptable Macronutrient Distribution Ranges for Adults

79

Table 5.3 Factors That Affect Fluid Requirements

84

Table 5.4 Estimated Energy Needs Based on Body Weight

136

Table 8.1 Summary of Dietary Intervention and Physical Activity Studies

144

Table 8.2 Dietary Intervention Trials in Cancer Survivors

523

Box 24.5 Evidence for Nutrition and Lifestyle Advice for Prostate Cancer Survivors

531

Box 25.1 Thyroid Cancer Statistics, in the United States, 2020

535

Box 25.2 Explanation for Inconsistencies in Low-Iodine Diet Guidelines

536

Box 25.3 Low-Iodine Diet

554

Box 26.1 Guidelines for the Use of Artificial Nutrition in Patients With Advanced Cancer

557

Box 26.2 Additional Resources Related to Palliative and Hospice Care

565

Box 27.1 Terpenoids Found in Cannabis and Their Effects

569

Box 27.2 Suggested Contraindications and Precautions for Cannabinoid Use

571

Box 27.3 Commonly Experienced Adverse Effects of Cannabis-Based Medicines by Prevalence

571

Box 27.4 Reported Drug-Cannabinoid Interactions

572

Box 27.5 Additional Resources Related to Cannabis Use

225

Table 12.1 Administration of Enteral Feeding

237

Table 12.2 Macronutrients in Parenteral Nutrition Solutions for Adults

238

Table 12.3 Standard Parenteral Electrolyte Requirements for Adults

238

Table 12.4 Standard Parenteral Trace Element Additives for Adults

239

Table 12.5 Standard Parenteral Vitamin Additives for Adults

260

Table 13.1 Pediatric Malnutrition Consensus Criteria

262

Table 13.2 Estimated Percentage of Total Body Weight of Missing Limbs for Various Amputation Levels

265

Table 13.3 Estimated Energy Requirement Equations for Pediatrics

265

Table 13.4 Physical Activity Factors for Estimated Energy Requirement Equations

266

Table 13.5 Resting Energy Expenditure Equations for Critically Ill Children

267

Table 13.6 Estimating Protein Needs in Pediatric Patients With Cancer

268

Table 13.7 Daily Adequate Intake Levels for Calcium

268

Table 13.8 Suggested Vitamin D Status Definitions for Pediatric Patients with Cancer

268

Table 13.9 Recommended Dietary Allowances for Vitamin D

308

Table 15.1 Average Time Until Neutrophil Engraftment by Type of Transplant

357

Table 17.1 Isoflavone Content of Soy Foods

359

Table 17.2 Docosahexaenoic Acid and Eicosapentaenoic Acid Content of Seafoods

407

Table 19.1 Gastrointestinal Cancer Statistics, United States

408

Table 19.2 Risk Factors for Different Types of Gastrointestinal Cancers



Figures

2

Figure 1.1 Trends in 5-year cancer survival rates by race

6

Figure 1.2 Possible effects of nutrients on various stages of carcinogenesis

38

Figure 3.1 Strength of the evidence for excess body fatness and increased cancer risk

45

Figure 3.2 Stages of cancer cachexia

82

Figure 5.1 Decision tree for identifying appropriate predictive equation for energy needs

93

Figure 6.1 The autonomic nervous system

134

Figure 8.1 Lifestyle interventions for symptoms experienced by cancer survivors

158

Figure 9.1 Conventional modalities of cancer treatment

186

Figure 10.1 Possible acute side effects of site-specific radiation therapy

251

Figure 13.1 Distribution of childhood cancer diagnoses per year, United States

252

Figure 13.2 Percentage survival in childhood cancer patients by diagnosis, ages 0 to 19

261

Figure 13.3 Nutrition screening tool for childhood cancer (SCAN) for identifying patients at high risk for malnutrition

281

Figure 14.1 Hematologic malignancy types

449

Table 20.1 Pancreatic Enzyme Replacement Products (Pancrelipase) Approved by the Food and Drug Administration

449

Table 20.2 Pancreatic Enzyme Replacement Dosing Regimens

457

Table 20.3 Intestinal Transit-Inhibiting Medications

499

Table 23.1 Statistics for Gynecologic Cancers, United States, 2020

547

Table 26.1 Prevalence of Specific Nutrition-Related Symptoms in Patients With Cancer

568

Table 27.1 Cannabis Pharmacokinetics by Route of Administration

307	417	450
<i>Figure 15.1</i> Selected conditioning regimens of differing dose intensities	<i>Figure 19.2</i> The biliary system and types of cholangiocarcinoma	<i>Figure 20.6</i> Pancreatic enzyme replacement optimization
332	422	475
<i>Figure 16.1</i> Major parts of the brain	<i>Figure 19.3</i> Selected surgeries for colorectal cancer	<i>Figure 21.1</i> Normal anatomy of the head and neck region
348	435	488
<i>Figure 17.1</i> Types of breast cancer	<i>Figure 20.1</i> Normal anatomy of the abdominal region and pancreas	<i>Figure 22.1</i> The four subtypes of lung cancer
378	442	503
<i>Figure 18.1</i> Esophagectomy	<i>Figure 20.2</i> Pancreaticoduodenectomy (resected anatomy)	<i>Figure 23.1</i> Sites and types of gynecologic cancers
383	443	516
<i>Figure 18.2</i> Normal anatomy of the stomach	<i>Figure 20.3</i> Pancreaticoduodenectomy (anatomical reconstruction)	<i>Figure 24.1</i> Carcinoma of the prostate gland
385	444	533
<i>Figure 18.3</i> Types of reconstruction after gastrectomy	<i>Figure 20.4</i> Pylorus-preserving pancreaticoduodenectomy (anatomical reconstruction)	<i>Figure 25.1</i> The thyroid gland and subtypes of thyroid cancer
406	445	550
<i>Figure 19.1</i> Cancers of the liver, bile duct, gallbladder, small bowel, colon, rectum, and anus	<i>Figure 20.5</i> Distal pancreatectomy	<i>Figure 26.1</i> Sample hospice initial nutrition assessment

Contributors



Alice Bender, MS, RDN
*Consultant, American
Institute for Cancer Research
Washington, DC*

Michelle Bratton, RDN, CSO
*Clinical Nutritionist,
University of Arizona
Cancer Center
Tucson, AZ*

**Laura Brown, MS, RD,
CSO, CNSC**
*Oncology Dietitian, SCL
Health, Cancer Centers
of Colorado
Lafayette, CO*

**Jennifer Caceres, MS, RD,
CSP, LDN**
*Operations Manager,
Nicklaus Children's Hospital
Miami, FL*

**Audrey Caspar-Clark, MA,
RDN, LDN**
*Advanced Clinical Dietitian
Specialist, Hospital of
the University of
Pennsylvania, Department
of Radiation Oncology
Philadelphia, PA*

**Karen Collins, MS, RDN, CDN,
FAND**
*Consultant and Nutrition
Advisor, American Institute
for Cancer Research
Bemus Point, NY*

**Tracy E. Crane, PhD,
MS, RDN**
*Assistant Professor of
Nursing, Public Health and
Nutrition Science,
University of Arizona
Tucson, AZ*

Alison Donato, RDN, CSO, CD
*Registered Dietitian,
MultiCare Health System
Tacoma, WA*

Colleen Gill, MS, RDN, CSO
*Private Practice Dietitian,
Nutrition Foundations, LLC
Denver, CO*

**Alicia Gilmore, MS, RD,
CSO, LD**
*Clinical Instructor, School
of Health Professions at
University of
Texas Southwestern
Medical Center
Dallas, TX*

**Ally F. Gottfried, MFN, RDN,
CSO, LD**
*Clinical Dietitian,
Community Cancer Center
Roseburg, OR*

**Barbara L. Grant, MS, RDN,
CSO, FAND**
*Oncology Dietitian
Nutritionist, Saint Alphonsus
Cancer Institute
Boise, ID*

**Gretchen B. Gruender, MS,
RDN, CSO, CD**
*Clinical Dietitian
Seattle, WA*

Kathryn K. Hamilton, MA,
RDN, CSO, CDN, FAND
*Outpatient Oncology
Dietitian Nutritionist,
Morristown Medical Center,
Morristown, NJ*

Jill Hamilton-Reeves, PhD,
RDN, CSO, NSCA-CPT
*Associate Professor,
University of Kansas
Medical Center
Kansas City, KS*

Katie Harper, MS, RD,
CNSC, CSO
*Clinical Dietitian, University
of Colorado Hospital
Aurora, CO*

Rachel Hill, RD, CSO,
LD, CNSC
*Clinical Dietitian, Cook
Children's Medical Center
Fort Worth, TX*

Elizabeth A. Huddleston,
MS, RDN
*Registered Dietitian
Nutritionist, Compassus
Hospice and Palliative Care
Branson, MO*

Maki Inoue-Choi, PhD,
MS, RD
*Staff Scientist, Metabolic
Epidemiology Branch,
Division of Cancer
Epidemiology and
Genetics, National Cancer
Institute, National Institutes
of Health, HHS
Bethesda, MD*

Liz Isenring, PhD, AdvAPD
*Director of LINC Nutrition,
Adjunct Honorary Professor,
Master of Nutrition
and Dietetic Practice,
Bond University
Robina, QLD, Australia*

Sandeep (Anu) Kaur, MS,
RDN, RYT-500
*Nutrition Research
Consultant, Certified
WellCoach, Registered
Yoga Teacher, www
.ANuHealthyYou.com
Ashburn, VA*

Nicole Kiss, BSc, PhD,
MNutDiet
*Senior Clinical Research
Fellow, Institute for Physical
Activity and Nutrition,
Deakin University
Burwood, VIC, Australia*

Natalie Ledesma, MS,
RD, CSO
*Clinical Nutrition Specialist,
Smith Integrative Oncology
and UCSF Helen Diller
Family Comprehensive
Cancer Center
Corte Madera, CA*

Maureen S. Leser, MS,
RDN, LD
Leesburg, FL

Rhone M. Levin, MEd, RDN,
CSO, LDN, FAND
*Oncology Dietitian, Duke
University Hospital,
Adult Oncology
Durham, NC*

Greta Macaire, MA, RD, CSO
*Oncology Registered
Dietitian Nutritionist,
University of California
San Francisco Helen Diller
Family Comprehensive
Cancer Center
San Francisco, CA*

Kerry K. McMillen, MS, RD,
CSO, FAND
*Manager, Medical Nutrition
Therapy, Seattle Cancer
Care Alliance
Seattle, WA*

**Kacie Merchand, MS, RD,
CSO, LD**
*Clinical Oncology Dietitian,
formerly at Norris Cotton
Cancer Center, Dartmouth-
Hitchcock Medical Center
Lebanon, NH*

**Kristen Miller, MS, RD,
CSP, CLEC**
*Pediatric Clinical Dietitian,
Oncology and Ketogenic
Diet, Children's Hospital
Orange County
Orange, CA*

**Jeannine B. Mills, MS, RDN,
CSO, LD**
*Board Certified Specialist in
Oncology Nutrition, Norris
Cotton Cancer Center,
Dartmouth-Hitchcock
Medical Center
Lebanon, NH*

**Kelli Oldham, MS, RDN,
CSO, LDN**
*Registered Dietitian, Vidant
Medical Center
Greenville, NC*

Amy Patton, RD, CSO, CNSC
*Associate Director, Hospital
Dietetics, The Ohio State
University Wexner Medical
Center and Arthur G. James
Cancer Hospital
Columbus, Ohio*

**Maria Q.B. Petzel, RD, CSO,
LD, CNSC, FAND**
*Senior Clinical Dietitian,
The University of Texas MD
Anderson Cancer Center
Houston, TX*

**Karen Ringwald-Smith, MS,
RDN, LDN, FAND**
*Project Manager, St. Jude
Children's Research Hospital
Memphis, TN*

**Kim Robien, PhD, RD, LD,
CSO, FAND**
*Associate Professor,
Department of Exercise
and Nutrition Services,
Milken Institute of Public
Health, George Washington
University
Washington, DC*

**Shayne Robinson, RD,
CSO, CDN**
*Clinical Dietitian, Herbert
Irving Comprehensive
Center, New York
Presbyterian, Columbia
University Irving
Medical Center
New York, NY*

**Lindsay Rypkema, RD,
CSP, CLEC**
*Clinical Dietitian, Children's
Hospital Orange County
Orange, CA*

Nancy Sacks, MS, RD, LDN
*Pediatric Oncology
Nutritionist, Research
Coordinator, The Children's
Hospital of Philadelphia,
Department of Nursing and
Clinical Care Services and
Center for Childhood
Cancer Research and
Division of Oncology
Philadelphia, PA*

Megan Schoenfeld, RD
*Clinical Research Dietitian,
National Institutes of Health
Clinical Center
Bethesda, MD*

**Cynthia A. Thomson, PhD,
RDN, FAND, FTOS**
*Professor, Health Promotions
Sciences, University
of Arizona, Mel & Enid
Zuckerman College of Public
Health, University of Arizona
Associate Director
Population Sciences,
University of Arizona
Cancer Center
Tucson, AZ*

Cheryl D. Toner, MS, RDN
*Director of Food Sector
Engagement, American
Heart Association
Washington, DC*



**Kelay E. Trentham, MS, RDN,
CSO, FAND**
*Lead Oncology Dietitian,
MultiCare Regional Cancer
Center
Tacoma, WA*

Elaine B. Trujillo, MS, RDN
*Nutritionist, National
Cancer Institute, National
Institutes of Health
Rockville, MD*

**Erin Williams, RD,
CSO, CNSC**
*Clinical Dietitian, University
of Colorado Cancer Center
Aurora, CO*

Reviewers

Heather Bell-Temin, MS, RDN,
CSO, FAND
*American Oncology
Network, LLC
Fort Myers, FL*

Shanna B. Yang, MPH, RDN
*Metabolic Research Dietitian,
National Institutes of
Health Clinical Center,
Nutrition Department
Bethesda, MD*

Katie Birks, RD, CSO
*Contract Dietitian
Denver, CO*

Janice Newell Bissex, MS,
RDN, FAND
*CEO, Jannabis Wellness
Professor, John Patrick
University School of
Integrative and
Functional Medicine
Melrose, MA*

Michelle Bratton, RDN, CSO
*Clinical Nutritionist,
University of Arizona
Cancer Center
Tucson, AZ*

Tricia Cox, MS, RD, CNSC, LD
*Oncology Dietitian,
Baylor Scott and White
Medical Center
Dallas, TX*

Sharon Day, RD, CSO,
CNSC, MBA
*Director of Integrative
Services and Chief of
Nutrition, Cancer Treatment
Centers of America
Goodyear, AZ*

Heidi Ganzer DCN, RDN,
CSO, LD
*Allina Health Cancer Institute
Rochester, MN*



Sommer Gaughan, RD, CSO
*Registered Dietitian,
University of Colorado
School of Medicine,
Department of Pediatrics
Aurora, CO*

Kristy Gibbons, MS, RD, CSP,
CSO, LDN
*Lead Clinical Dietitian, St.
Jude Children's
Research Hospital
Memphis, TN*

Alicia Gilmore, MS, RD,
CSO, LD
*Clinical Instructor, School of
Health Professions at
University of Texas
Southwestern
Medical Center
Dallas, TX*

Jodie Greear, MS, RD,
CSO, LDN
*Clinical Dietitian, St Jude
Children's Research Hospital
Memphis, TN*

Lisa Heneghen, MPH, RD,
CSO, CNSC
*Clinical Dietitian, UCHHealth
Aurora, CO*

Melissa Kingery, MS, RD,
CSO, LD/N
*Clinical Oncology Nutritionist,
Florida Cancer Specialists
Fort Myers, FL*

Heather Lazarow, MS, RD,
CSO, LDN
*Advanced Practice Clinical
Dietitian Specialist, Hospital
of the University
of Pennsylvania
Philadelphia, PA*

Natalie Ledesma, MS,
RD, CSO
*Clinical Nutrition Specialist,
Smith Integrative Oncology
and UCSF Helen Diller
Family Comprehensive
Cancer Center
Corte Madera, CA*

Paula Charuhas Macris, MS,
RD, CSO, FAND, CD
*Nutrition Education
Coordinator, Seattle Cancer
Care Alliance
Seattle, WA*

Jeannine B. Mills, MS, RDN,
CSO, LD
*Board Certified Specialist in
Oncology Nutrition, Norris
Cotton Cancer Center,
Dartmouth-Hitchcock
Medical Center
Lebanon, NH*

Samantha Peterson, MS,
RD, CSO
*Registered Dietitian, Simply
Wellness LLC
Goodyear, AZ*

Kim Robien, PhD, RD, LD,
CSO, FAND
*Associate Professor,
Department of Exercise and
Nutrition Services, Milken
Institute of Public
Health, George
Washington University
Washington, DC*

Sara Schumacher, MS, RD,
CSO, CNSC
*Clinical Oncology Dietitian,
Cancer Treatment Centers
of America
Goodyear, AZ*

Renee Thornton, MS, RD,
CSO, LDN
*Clinical Oncology Dietitian,
Cancer Treatment Centers
of America
Philadelphia, PA*

Preface

Anne Coble Voss, PhD, RDN, LDN

Valaree Williams, MS, RD, CSO, LDN, CNSC, FAND

Editors, *Oncology Nutrition for Clinical Practice*, Second Edition

Oncology Nutrition for Clinical Practice, first published in 2013 by the Oncology Nutrition Dietetic Practice Group, has served as a vital text for registered dietitian nutritionists (RDNs) providing nutrition care to patients with cancer. The intent of this fully updated second edition is to provide both evidence- and experienced-based information for application in clinical practice.

Written and reviewed by knowledgeable RDNs practicing in oncology, this comprehensive resource can be read cover to cover, especially by those new to oncology nutrition, or individual chapters can serve as a guide for clinical practice for both experienced oncology practitioners as well as those who may only work occasionally with patients with cancer. To complement this edition, the new *Oncology Nutrition: Educational Handouts and Resources*, also developed by the Oncology Nutrition Dietetic Practice Group, provides handouts and practical guidance for the nutrition professional to use when counseling their patients with cancer.

This second edition addresses nutrition through the cancer continuum—from carcinogenesis and prevention to treatment, survivorship, and palliative care. All steps of the Nutrition Care Process are addressed with chapters covering nutrition screening, assessment, diagnosis and treatment of nutrition impact symptoms, and intervention and monitoring through medical nutrition therapy. Thirteen chapters address medical nutrition therapy of specific cancer sites, with a new chapter covering hematological malignancies. New to this edition is a chapter that provides rationale and guidance for the use of medical cannabis in cancer treatment.

To direct readers to the most current cancer treatments, in light of the rapidly changing nature of treatment regimens, an overview of treatment modalities and their associated nutrition impact symptoms are discussed in Chapters 9 and 10, and within the medical nutrition therapy chapters, readers are directed to the National Comprehensive Cancer Network (NCCN) guidelines for treatment of cancer by site for regimens for each specific cancer site discussed. NCCN Guidelines are available at www.nccn.org/professionals (free access after registration).

To demonstrate the use of standardized language, sample cancer-specific nutrition diagnosis

(PES) statements, developed through collaboration with the Oncology Nutrition Dietetic Practice Group and Academy of Nutrition and Dietetics Nutrition Care Process staff, are included at the end of each medical nutrition therapy chapter. These sample nutrition diagnostic statements support the efforts of the Oncology Nutrition Dietetic Practice Group to increase use of standardized language in documentation of patient care by the RDN to support nutrition outcome measures in the future. In addition to concise, uniform, and complete documentation of nutrition interventions and outcomes by the RDN, standardized language is also essential to the evaluation and coordination of care, determination of the type, level, and complexity of the nutrition intervention, and—most importantly—to the generation of new understanding of the effectiveness and outcomes of nutrition intervention provided by the oncology RDN.

Of special note is the use of the term *cancer survivor* in this edition. Although the National Cancer Institute and some other groups consider a patient to be a survivor from the time of diagnosis until the end of life, this book uses cancer survivor to describe the period posttreatment, and separate from diagnosis, treatment, and end-of-life care. This definition helps to differentiate the nutrition care provided to those living after cancer therapy who may be disease-free or who have stable disease and desire medical nutrition therapy to maintain or improve quality of life and institute measures to prevent future cancers (see Chapters 2 and 8).

We are grateful to the contributors for sharing their expertise and to the reviewers for providing thoughtful, thorough review. With the known impact of nutrition on the development, treatment, and outcomes of cancer, we hope that readers find this second edition to be an essential and useful professional resource to further their expertise and practice.

About the Editors and the Oncology Nutrition Dietetic Practice Group

SAMPLE

Not for Print
or Resale

Anne Coble Voss, PhD, RDN, LDN, writes, lectures and consults on oncology nutrition and oncology nutrition research design following a career as an associate research fellow in the Volwiler Society at Abbott Nutrition.

Dr Voss has experience in the creation of national and international oncology nutrition guidelines and has extensive experience in oncology nutrition research. She held leadership positions in local and state dietetic associations and the Oncology Nutrition Dietetic Practice Group and sat on the Council on Research for the Academy of Nutrition and Dietetics. Dr Voss worked for The Ohio State University College of Medicine, The Ohio State University Hospitals, and Johns Hopkins Hospital. She has published over 75 journal articles, monographs, and book chapters.

Dr Voss earned her undergraduate degree in medical dietetics and a PhD in nutritional biochemistry from The Ohio State University. She recently received the Academy of Nutrition and Dietetics Distinguished Practice Award, The Ohio State University Distinguished Alumni Award, a President's Award, and a Luminary Award from Abbott Laboratories.

Valaree Williams, MS, RD, CSO, LDN, CNSC, FAND is a clinical dietitian at the Hospital of the University of Pennsylvania of the University of Pennsylvania Health System in Philadelphia. Over the past 9 years, she has specialized in caring for patients with cancer, focusing on cancers of the gastrointestinal tract. She serves in several volunteer roles for the Academy of Nutrition and Dietetics and is a commissioner for the Commission on Dietetic Registration. Additionally, she has contributed to textbooks on nutrition for patients with cancer.

Valaree received a bachelor of science degree in dietetics from the Indiana University of Pennsylvania, completed her dietetic internship at the University of Pittsburgh Medical Center Presbyterian-Shadyside, and obtained her master of health sciences degree from Chatham University.

Oncology Nutrition Dietetic Practice Group (ON DPG) is a dietetic practice group of the Academy of Nutrition and Dietetics with the mission of empowering members as oncology nutrition leaders and experts through advocacy, education, and research. Efforts of the ON DPG focus on oncology nutrition practice in areas including research, prevention, treatment, recovery, palliative care, and hospice. The ON DPG provides oncology nutrition resources for the public in addition to supporting dietetic professionals with evidence-based tools and professional networking opportunities to assist with managing the complexities of oncology nutrition practice.

Chapter 1

Overview of Cancer, Carcinogenesis, and the Role of Nutrition

Maki Inoue-Choi, PhD, MS, RD

Kim Robien, PhD, RD, LD, CSO, FAND

SAMPLE Print
Not for Resale

The term *cancer* refers to a group of neoplastic diseases characterized by the uncontrollable growth and spread of abnormal cells, which if left untreated may result in death. There are more than 100 types of cancer, each with its own etiology, progression, recommended treatment, and prognosis.¹

This chapter addresses the following:

- cancer statistics in the US adult population
- health care expenditures for cancer care
- cancer screening
- cancer classification (staging) methods
- the role of nutrition across the cancer continuum

Box 1.1 lists the five most common types of new cancer cases in the United States for men and women in order of most to least common.



Box 1.1

The Five Most Common Types of New Cancer Cases in the United States²

Men	Women
1. Prostate	1. Breast
2. Lung and bronchus	2. Lung and bronchus
3. Colorectal	3. Colorectal
4. Urinary (bladder)	4. Uterine
5. Melanoma (skin)	5. Thyroid

Cancer Statistics

Using data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute (NCI), a premier source for cancer statistics in the United States, the American Cancer

Society (ACS) estimated that approximately 1.8 million new cancer cases would be diagnosed in 2020.¹ Cancer is the second most common cause of death in the United States, after heart disease; it accounts for nearly one in every four US deaths and caused approximately 600,000 deaths in 2020.²

Approximately 40% of men and 38% of women in the United States will develop cancer during their lifetime.¹ Among all racial and ethnic groups in the nation, Blacks and non-Hispanic Whites have the highest cancer incidence rates.³

The 5-year survival rate for all cancers has improved from 49% for cancers diagnosed between 1975 and 1977 to 69% for cancers diagnosed between 2009 and 2015; yet it remains lower among Blacks (64%) than Whites (70%) (see Figure 1.1 on page 2).² Survival rates vary significantly by cancer type and stage at the time of diagnosis.

Cost of Cancer Care

The financial costs of cancer care are a burden for cancer patients, their families, and society. Individually, cancer survivors face not only direct costs related to health care expenses but also lost income due to illness, decreased productivity, and premature mortality.⁴

The NCI estimates that the cost of cancer care in 2010 was \$157 billion. This figure was expected to reach \$173 billion by 2020, given the growth and aging of the US population.^{4,5} Additional costs will occur with the increase in cancer incidence expected with increased longevity.⁶ Even if cancer incidence remains constant or decreases, the absolute number




Figure 1.1
Trends in 5-year cancer survival rates by race

Adapted from American Cancer Society. Cancer Facts & Figures 2020. American Cancer Society; 2020. Accessed January 5, 2021. www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html. See reference 2.

of people treated for cancer will increase, as the overall population increases and ages. The largest projected increase in costs for 2020 was expected to result from long-term continuing care for survivors of breast cancer and prostate cancer, the most common cancers in women and men, respectively.⁵

Cancer Screening

Regular screening can result in early detection of precancerous lesions and diagnosis of cancer at an early stage, when it is most treatable. “Early” cancer detection is the identification of tumors before they become palpable; early detection is an active area of cancer research with the potential to significantly decrease cancer morbidity, mortality, and health care costs.⁵ Over the last few decades, significant decreases in death rates from certain cancers, such as breast and colorectal, have been attributed largely to increased screening, as well as to advancements in treatment options.² There are several types of screening that can be employed:

- Palpation (physical examination) (eg breast or testicle self-examination or a skin examination)

is the most common type of screening; however, by the time a cancer is detected by palpation, it can be fairly advanced.

- Blood tests, such as prostate-specific antigen testing, are used to determine levels of circulating tumor cell metabolites.
- Imaging procedures, such as mammograms and colonoscopies, can detect cancers that are too small to feel by physical examination.
- Molecular techniques (for genetic biomarkers), such as genotyping or gene expression assays, look for certain genetic mutations that are linked to some types of cancer. Researchers are also exploring possible use in early cancer detection, as well as many radiographic techniques.

With all types of screening, false test results can occur. For example, test results might appear to be abnormal, even though there is no cancer. False-positive results can cause anxiety in patients and are usually followed by more invasive tests and procedures. Conversely, screening results might appear to be normal, even though a cancer

is present. False-negative test results may delay appropriate medical care. The ACS publishes annual cancer screening guidelines on its website (www.cancer.org).⁷

Cancer Staging

Staging is a process for describing the severity of a cancer based on the extent of disease and whether the primary tumor has spread to other areas of the body (metastasized) at the time of diagnosis. Staging is essential to determining the appropriate treatment plan and estimating prognosis at the time of diagnosis. A number of different staging systems are used to classify cancer, but the tumor, (lymph) node, metastasis (TNM) classification system^{8,9} is one of the most widely used tumor staging tools,

especially for solid tumors. Each tumor is assigned a grade for each letter: the T grade reflects the size and extent of the tumor; the N grade is for the extent of spread to local lymph nodes; and the M grade indicates the presence or absence of distant metastasis. The number added to each letter indicates the size or extent of the primary cancer and the extent of cancer spread (see Box 1.2).

For some cancers, the TNM classification is not the only system that determines the stage. For most cancers, a grading system is also used. Grade is a measure of how abnormal the cancer cells look under the microscope; this is called differentiation (see Box 1.3 on page 4). Grade can be important because cancers that look more abnormal, or that are more differentiated, tend to grow and spread faster. Each type of cancer has a unique grading

Box 1.2

Summary of the Tumor, Lymph Node, Metastasis (TNM) Classification System⁹

<i>Primary tumor (T)</i>		<i>Lymph nodes (N)</i>	
Grade	Definition	Grade	Definition
TX	Tumor cannot be evaluated	NX	Regional lymph nodes cannot be evaluated
T0	No evidence of tumor	N0	No regional lymph node involvement
Tis	<i>Carcinoma in situ</i> (CIS): Abnormal cells are present but not spread to neighboring tissues Although not cancer, CIS may become cancer	N1	Involvement of regional lymph nodes
T1	Tumor not palpable or visible by imaging	N2	(number of lymph nodes indicates extent of spread)
T2	Tumor confined to the primary cancer site	N3	
T3	Tumor extends to the neighboring tissue	<i>Distant metastasis (M)</i>	
T4	Metastatic disease	Grade	Definition
		MX	Distant metastasis cannot be evaluated
		M0	No distant metastasis
		M1	Distant metastasis is present

system. Tumors also are described according to their nuclear grade, which describes the size and shape of the nucleus in the tumor cells and the percentage of tumor cells that are actively dividing.⁸



Box 1.3

Tumor Grading System of the American Joint Committee on Cancer⁹

Grade	Description
GX	Grade cannot be assessed (undetermined grade)
G1	Well-differentiated (low grade)
G2	Moderately differentiated (intermediate grade)
G3	Poorly differentiated (high grade)
G4	Undifferentiated (high grade)

Carcinogenesis

Carcinogenesis is the process by which normal cells transform into cancer cells, usually as a result of accumulated genetic damage. Carcinogenesis is commonly described as a process consisting of three phases:

1. Initiation, during which normal cells develop some type of DNA damage
2. Promotion, during which initiated cells are stimulated to grow
3. Progression, when the tumor grows rapidly and invades neighboring tissues

In the initiation phase, normal cells develop genetic damage as a result of exposure to environmental factors, such as radiation, chemicals, or viruses. DNA damage also can result from chronic inflammation due to long-term disease. Some of

these factors damage DNA directly. Others, especially some chemicals, attach to the DNA and prevent normal transcription and translation of the DNA.¹⁰

Under normal conditions, cellular processes involving DNA repair enzymes allow cells to repair individual instances of DNA damage. If the damage cannot be repaired, it can trigger what is called cell cycle arrest, which results in a process known as apoptosis (programmed cell death). However, if the initiated cell does not undergo cell cycle arrest and apoptosis, it could progress to become cancer. Damage that occurs within the DNA repair genes can lead to alterations in these normal repair processes and stimulate uncontrolled tumor growth.¹⁰

Although genetic susceptibility increases the risk for developing certain types of cancer, other factors commonly associated with cancer incidence and progression include:

- internal environmental factors, such as hormones and the immune system;
- external environmental factors, such as infections and exposure to environmental toxins; and
- unhealthy behaviors, such as smoking, excessive sunlight exposure, and unhealthy diet.^{11,12}

These factors may act in combination to initiate or promote carcinogenesis. Estimates are that one-third of cancer deaths are smoking-related, and another third are related to overweight or obesity, physical inactivity, and poor diet.¹³

Nutrition and Carcinogenesis

Evidence, primarily from in vitro studies, suggests that nutrients can play a protective role during all stages of carcinogenesis (see Figure 1.2 on page 6).¹⁰ Chapter 2 addresses the role of nutrition in cancer prevention in more detail. In general, mechanisms by which food components might have protective effects in preventing cancer incidence and progression include:

- promotion of detoxification of carcinogens;
- prevention of oxidative damage to DNA;
- inhibition of the cell cycle or induction of apoptosis in initiated cancer cells; and
- support of DNA repair, cell differentiation, hormone regulation, carcinogen metabolism, and anti-inflammatory responses.

The roles that energy balance and body weight play in cancer incidence and treatment outcomes are becoming better understood; however, the exact mechanisms are complex and not fully known. Higher levels of adiposity and lower lean body mass have consistently been associated with increased risk for many types of cancers, as well as for poor treatment outcomes.¹⁴ Excess adipose tissue has been shown to alter the interactions between insulin, growth hormone, insulin-like growth factors, sex hormones, and adipocyte-derived cytokine levels to precipitate favorable environments for cancer incidence and progression.¹⁵ See Chapter 3 for more details about the relationship between energy balance and cancer incidence.

Certain diet-related factors also might increase the risk for developing cancer. For example, cooking meats at high temperatures (eg, grilling over an open flame) can precipitate formation of heterocyclic amines and polycyclic aromatic hydrocarbons, which have been shown to form DNA adducts (a portion of DNA attached to a cancer-causing chemical).^{15,16} Foods also can serve as a vehicle for exposure to environmental toxins, such as aflatoxins (a family of fungal toxins associated with peanuts and other agricultural crops), which form DNA adducts,¹⁷ or the endocrine-disrupting chemical bisphenol A (BPA, found in plastic bottles and food containers), which can stimulate proliferation of estrogen-mediated cancers, such as breast or ovarian cancer.¹⁸ Excessive doses of nutrients more than the Recommended Dietary Allowance also might enhance progression of initiated cancer cells.^{11,12}

Role of Nutrition in Cancer Treatment

Primary treatments for cancer include surgery, radiation, chemotherapy, hormone therapy, immunotherapy, biological therapy, targeted therapy, transplantation, and various combinations of these modalities.¹⁹ Treatment selection depends on the cancer type, stage of disease, and other factors, such as the patient's age and comorbid conditions. Supportive care with nutrition and physical activity interventions, as well as complementary and alternative medicine approaches, is increasingly being used.

As noted previously, nutrients can play different roles at different stages of carcinogenesis (see Figure 1.2 on page 6). For example, folate is a vital nutrient for maintaining accurate DNA synthesis and repair; thus, adequate folate intake is important for preventing many types of cancers. However, once carcinogenesis has been initiated, folate can facilitate DNA synthesis in cancer cells, leading to proliferation and expansion of the tumor.²⁰ Methotrexate, an antifolate chemotherapeutic agent, targets this metabolic process by inhibiting folate-mediated DNA synthesis, thus stopping cancer-cell proliferation. Folate in the form of leucovorin calcium may be used to “rescue” patients from methotrexate toxicity or, alternatively, to enhance the effectiveness of drugs, such as fluorouracil (5-FU), that target enzymes that use folate as a cofactor.²¹

Chemotherapeutic agents are designed to kill cancer cells, which often grow and divide more rapidly than normal cells. However, most chemotherapy drugs are indiscriminate and also damage normal cells, such as blood cells in the bone marrow, cells in the digestive tract (including the mouth, esophagus, stomach, and intestines), cells in the reproductive system, and hair follicles.¹⁹ Common side effects of chemotherapy, such as loss of appetite, nausea, mucositis, and diarrhea, result from this

Initial exposure leading to DNA adduct formation and DNA damage




Figure 1.2
Possible effects of nutrients on various stages of carcinogenesis

Healthy cells can develop genetic damage from exposure to environmental factors, such as radiation, chemicals, or viruses. Nutrients can play a protective role in these early carcinogenetic processes.

Adapted from World Cancer Research Fund/American Institute for Cancer Research. The cancer process. In: *Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continuous Update Project Expert Report 2018*. Accessed January 12, 2020. www.wcrf.org/dietandcancer/cancerprocess. See reference 10.

cellular damage. Radiation therapy can also cause side effects by damaging normal, healthy cells near the treatment site.¹⁹ Nutrition and pharmacologic intervention can help prevent significant malnutrition and loss of muscle mass caused by treatment side effects. Studies suggest that nutrition intervention during cancer treatment is associated with fewer treatment-related side effects,²²⁻²⁵ fewer hospitalizations,²⁴⁻²⁶ and improved quality of life.^{22,23,27} The role of nutrition interventions during site-specific cancer treatment is discussed in further detail in Chapters 13 through 25.

The Role of Posttreatment Nutrition

Nutrition remains a fundamental component of recovery after cancer treatment. Individuals who have completed cancer treatment might experience treatment-related late effects, such as changes in body composition, bone density, or cardiovascular complications. Cancer recurrence or second primary cancers also can be a concern. Healthy dietary choices are an important part of an overall strategy to prevent or manage these conditions. See Chapter 8 for further discussion of the role of nutrition after cancer treatment.

Summary

As shown in Box 1.4 on pages 8 and 9, nutrition plays a significant role across the cancer continuum. A healthy diet and lifestyle can help decrease the risk of cancer development and can improve cancer outcomes. More research is needed to gain a clearer understanding of the specific role nutrition plays in cancer biology, treatment regimens, and management of treatment side effects.



Box 1.4

Potential Nutrition-Related Concerns and Outcomes Across the Cancer Continuum

Diagnosis

Stage in continuum	Cancer prevention	Initial treatment
Potential nutrition concerns	<ul style="list-style-type: none">▪ Obesity, loss of muscle mass▪ Energy-dense food intake▪ Excessive micronutrient intake from dietary supplements▪ Food contaminants (toxins, chemicals)	<ul style="list-style-type: none">▪ Treatment side effects (eg, nausea, vomiting, diarrhea, mucositis, taste changes)▪ Fatigue▪ Pain▪ Anorexia▪ Treatment-related cachexia▪ Immunosuppression▪ Weight or body-composition changes▪ Drug-nutrition interactions
Potential outcomes of nutrition interventions	<ul style="list-style-type: none">▪ Improved weight and body composition▪ Improved blood glucose control▪ Improved immune surveillance	<ul style="list-style-type: none">▪ Ability to adhere to scheduled treatment▪ Fewer infectious complications▪ Improved weight and body composition▪ Delay or prevention of disease progression▪ Improved chances of survival▪ Improved quality of life

Adapted from Robien K, Demark-Wahnefried W, Rock CL. Evidence-based nutrition guidelines for cancer survivors: current guidelines, knowledge gaps, and future research directions. *J Am Diet Assoc.* 2011;111(3):368-375. See reference 28.

≥5 Years After Diagnosis

Early posttreatment

- Fatigue
- Pain
- Endocrine disorders
- Weight or body-composition changes
- Cognitive deficits
- Dental caries or complications

Long-term cancer survivorship

- Weight loss or gain
- Decreased bone density
- Endocrine disorders
- Cardiovascular complications
- Cognitive deficits
- Dental caries or complications

- Decreased fatigue
- Improved functional status
- More rapid recovery from treatment
- Improved weight and body composition
- Decreased risk for cancer recurrence and subsequent primary cancers
- Improved chances of survival
- Improved quality of life

- Fewer late effects of treatment
- Improved functional status
- Improved weight and body composition
- Decreased risk of cancer recurrence and subsequent primary cancers
- Improved chances of survival
- Improved quality of life
- Decreased health care costs

References

1. What is cancer? National Cancer Institute website. September 2020. Accessed January 5, 2021. www.cancer.gov/about-cancer/understanding/what-is-cancer
2. American Cancer Society. *Cancer Facts & Figures 2020*. American Cancer Society; 2020. Accessed January 5, 2021. www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html
3. Noone AM, Howlader N, Krapcho M, et al, eds. SEER cancer statistics review, 1975–2015, National Cancer Institute. Surveillance, Epidemiology, and End Results Program website. Posted April 2018. Accessed June 8, 2020. https://seer.cancer.gov/csr/1975_2015
4. National Cancer Institute. Cancer Prevalence and Cost of Care Projections website. Accessed June 8, 2020. <https://costprojections.cancer.gov>
5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst*. 2011;103(2):117-128. doi:10.1093/jnci/djq495
6. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. *J Natl Cancer Inst*. 2008;100(9):630-641.
7. American Cancer Society Guidelines for the Early Detection of Cancer. American Cancer Society website. May 2018. Accessed June 8, 2020. www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html
8. Sobin LH, Wittekind C, International Union Against Cancer. *TNM: Classification of Malignant Tumors*. 6th ed. Wiley-Liss; 2002.
9. American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 8th ed. Springer; 2016.
10. World Cancer Research Fund/American Institute for Cancer Research. The cancer process. In: *Diet, Nutrition, Physical Activity and Cancer: A Global Perspective*. Continuous Update Project Expert Report 2018. Accessed January 12, 2020. www.wcrf.org/dietandcancer/cancer-process
11. World Cancer Research Fund/American Institute for Cancer Research. *Diet, Nutrition, Physical Activity and Cancer: A Global Perspective*. Continuous Update Project Expert Report 2018. Accessed April 30, 2020. www.wcrf.org/dietandcancer
12. Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. *CA A Cancer J Clin*. 2020;70:245-271. doi:10.3322/caac.21591
13. Willett WC. Balancing life-style and genomics research for disease prevention. *Science*. 2002;296(5568):695-698.
14. Demark-Wahnefried W, Schmitz KH, Alfano CM, et al. Weight management and physical activity throughout the cancer care continuum. *CA Cancer J Clin*. 2018;68(1):64-89.
15. Turesky RJ, Le Marchand L. Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. *Chem Res Toxicol*. 2011;24(8):1169-1214.
16. Turesky RJ. Formation and biochemistry of carcinogenic heterocyclic aromatic amines in cooked meats. *Toxicol Lett*. 2007;168(3):219-227.
17. De Ruyck K, De Boevre M, Huybrechts I, De Saeger S. Dietary mycotoxins, co-exposure, and carcinogenesis in humans: short review. *Mutat Res Rev Mutat Res*. 2015;766:32-41.
18. Shafei A, Ramzy MM, Hegazy AI, et al. The molecular mechanisms of action of the endocrine disrupting chemical bisphenol A in the development of cancer. *Gene*. 2018;647:235-243.
19. Treatments and side effects. American Cancer Society website. Accessed June 8, 2020. www.cancer.org/treatment/treatments-and-side-effects

20. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. *J Nutr*. 2000;130(2):129-132.
21. Robien K. Folate during antifolate chemotherapy: what we know . . . and do not know. *Nutr Clin Pract*. 2005;20(4):411-422.
22. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncol*. 2005;23(7):1431-1438.
23. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. *Head Neck*. 2005;27(8):659-668.
24. Odelli C, Burgess D, Bateman L, et al. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. *Clin Oncol (R Coll Radiol)*. 2005;17(8):639-645.
25. Paccagnella A, Morello M, Da Mosto MC, et al. Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. *Support Care Cancer*. 2010;18(7):837-845.
26. Hill A, Kiss N, Hodgson B, Crowe TC, Walsh AD. Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients. *Clin Nutr*. 2011;30(1):92-98.
27. Ollenschlager G, Thomas W, Konkol K, Diehl V, Roth E. Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. *Eur J Clin Invest*. 1992;22(8):546-553.
28. Robien K, Demark-Wahnefried W, Rock CL. Evidence-based nutrition guidelines for cancer survivors: current guidelines, knowledge gaps, and future research directions. *J Am Diet Assoc*. 2011;111(3):368-375.

Chapter 2

Nutrition and Cancer Prevention

Karen Collins, MS, RDN, CDN, FAND

Alice Bender, MS, RDN

SAMPLE
Print
Not for
Resale

A substantial proportion of cancer cases in the United States are preventable. An estimated 40% of cases could be prevented through healthful dietary patterns, regular physical activity, maintaining a healthy weight (low body mass index and low adiposity), avoiding tobacco and excess sun exposure, and getting certain vaccines and regular screenings.¹

In 2018, the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) jointly established recommendations for cancer prevention based on a structured and systematic approach of analyses and review of the literature on food, nutrition, physical activity, and cancer by an expert panel. These recommendations and the science behind them are outlined in this chapter.² The chapter also includes a section on emerging food and nutrition topics of special interest. These topics are being actively studied, but currently there is limited or inconsistent evidence regarding the effects of the various foods and practices on cancer risk.

Recommendations for Cancer Prevention

The 2018 World Cancer Research Fund and American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations are aimed at the overall prevention of cancer and are compatible with the *2020–2025 Dietary Guidelines for Americans*, which focus on promoting overall health, reducing the prevalence of overweight and obesity, and preventing diet-related chronic diseases.³ They also align with the American Cancer Society (ACS) guidelines on nutrition and physical activity for cancer prevention.⁴ Box 2.1 on pages 14 and 15 summarizes the WCRF/AICR recommendations for cancer prevention. Appendix A compares cancer prevention

diet and lifestyle recommendations from various organizations. Each section that follows addresses a WCRF/AICR recommendation and describes the link to specific cancers, the proposed mechanisms, and key practice points.

Adiposity and Weight Gain

Maintaining a healthy body weight throughout life may be the most important lifestyle factor in reducing cancer risk, second only to not using tobacco products.⁵ There is convincing evidence that a greater degree of body fatness—or greater adiposity—is a cause of cancers of the esophagus (adenocarcinoma), pancreas, colorectum, breast (postmenopausal), endometrium, liver, and kidney. Greater body fatness is probably also a cause of cancers of the stomach (cardia), gallbladder, ovaries, and mouth, pharynx, and larynx; and it has also been implicated in advanced prostate cancers.²

Excess body fatness could influence cancer risk through several possible mechanisms:

- Excess body fat is associated with insulin resistance, resulting in elevated levels of insulin and increased bioavailable insulin-like growth factor 1 (IGF-1).^{2,6} Insulin and IGF-1 can activate signaling pathways that promote growth and proliferation of cancer cells and inhibit apoptosis (programmed cell death).^{7–9}
- Overweight and obesity can lead to chronic low-grade systemic inflammation, which can

Appendix C

Select Dietary Supplements and Functional Foods

This information is designed to provide practitioners with available research on select dietary supplements and functional foods and how they relate to cancer. Its purpose is neither to condone nor to discourage use by patients. A patient's health care team can determine which supplements or foods are appropriate, if any.



616

Aloe
(*Aloe barbadensis miller*)

618

α -Lipoic acid

620

Black cohosh
(*Cimicifuga racemosa*)

622

Coenzyme Q10 (CoQ10)

624

Curcumin (*Cucurma longa*)

626

3,3'-Diindolylmethane (DIM)
and indole-3-carbinol (I3C)

628

Flaxseed
(*Linum usitatissimum*)

630

Garlic (*Allium sativum*)

632

Ginger (*Zingiber officinale*)

634

Ginkgo biloba

636

Glutamine

638

Green tea
(*Camellia sinensis*)

640

Melatonin

642

N-acetylcysteine (NAC)

644

Omega-3 fatty acids
eicosapentaenoic acid (EPA)
and docosahexaenoic acid
(DHA)

646

Quercetin

648

Reishi mushroom
(*Ganoderma lucidum*)

650

Resveratrol

652

Selenium

654

Silymarin

656

St. John's wort
(*Hypericum perforatum*)

658

Theanine

660

Turkey tail mushroom or
Yun Zhi (*Coriolus versicolor*,
Trametes versicolor,
Polyporus versicolor)

662

Vitamin D



Aloe (*Aloe barbadensis miller*)

A cactus-like plant, aloe is used predominantly in the form of a gel or a juice.¹⁻⁵

Reported anticancer benefits

May be useful for constipation

Reported anticancer concerns

Well tolerated and good safety data on aloe juice and aloe vera gel
Aloe latex used orally may be unsafe and may cause diarrhea

Evidence

Aloe use may delay radiation dermatitis in patients with head and neck cancer.²
In a randomized study, patients with lung cancer who consumed aloe mixed with honey three times daily during chemotherapy significantly increased response compared with those who had chemotherapy alone.³
Radiation proctitis significantly improved in patients who used aloe vera 3% ointment in a preliminary randomized controlled clinical trial.⁴

Comments

N/A

SAMPLE Print
Not for Resale

References

1. Aloe vera. National Center for Complementary and Integrative Health. Accessed May 27, 2020. www.nccih.nih.gov/health/aloe-vera
2. Rao S, Hegde SK, Baliga-Rao MP, et al. An aloe vera-based cosmeceutical cream delays and mitigates ionizing radiation-induced dermatitis in head and neck cancer patients undergoing curative radiotherapy: a clinical study. *Medicines (Basel)*. 2017 Jun 24;4(3). pii: E44.
3. Lissoni P, Rovelli F, Brivio F, et al. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. *In Vivo*. 2009;23:171-5.
4. Sahebnasagh A, Ghasemi A, Akbari J, et al. Successful treatment of acute radiation proctitis with aloe vera: a preliminary randomized controlled clinical trial. *J Altern Complement Med*. 2017;23(11):858-865.
5. Aloe. Natural Medicines Comprehensive Database. Accessed March 2018. <https://naturalmedicines.therapeuticresearch.com/databases/food-herbs-supplements/professional.aspx?productid=607>

SAMPLE
Not for Print
or Resale



α -Lipoic acid

α -Lipoic acid is a cellular antioxidant important for energy production that is naturally synthesized in the body.

Reported anticancer benefits

Improves insulin sensitivity and diabetes management
Aids with hypertension
May mitigate radiation damage
May reduce symptoms of neurotoxicity
Inhibits growth of breast, colon, lung, liver, and pancreatic cancer cells

Reported anticancer concerns

Generally, very well tolerated

Evidence

α -Lipoic acid used orally or intravenously seems to improve insulin sensitivity and fasting blood glucose levels in patients with type 2 diabetes.¹⁻⁴
 α -Lipoic acid is reported to inhibit tumor cells both in vitro and in vivo.⁵
 α -Lipoic acid has been found to reduce neuropathic symptoms and triglycerides and improve quality of life.⁶
 α -Lipoic acid administration is ineffective at preventing neurotoxicity caused by oxaliplatin or cisplatin.⁷ However, Opera (GAMFARMA), a combination product composed of α -lipoic acid, *Boswellia serrata*, methylsulfonylmethane, and bromelain, improved peripheral neuropathy symptoms in a prospective series of patients treated for neurotoxic chemotherapy; no significant toxicity or interaction was observed.⁸
 α -Lipoic acid reduced radiation-induced oral mucositis in rats with head and neck cancer in one study.⁹

Comments

α -Lipoic acid is both fat- and water-soluble and is thus able to function throughout the body.¹⁰
Dietary sources rich in α -lipoic acid include spinach, broccoli, and brewer's yeast.
The evidence for supplemental α -lipoic acid is still to be determined, but there appears to be potential benefit regarding insulin sensitivity, peripheral neuropathy, and mucositis.

References

1. Konrad T, Vicini P, Kusterer K, et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with Type 2 diabetes. *Diab Care*. 1999;22:280-7.
2. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled, pilot trial. *Free Rad Biol Med*. 1999;27:309-14.
3. Ansar H, Mazloom Z, Kazemi F, Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. *Saudi Med J*. 2011;32(6):584-588.
4. Porasuphatana S, Suddee S, Nartnampong A, et al. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. *Asia Pac J Clin Nutr*. 2012;21(1):12-21.
5. Feuerecker B, Pirsig S, Seidl C, et al: Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. *Cancer Biol Ther*. 2012;13(14):1425-1435.
6. Agathos E, Tentolouris A, Eleftheriadou I, et al. Effect of α -lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. *J Int Med Res*. 2018;46(5):1779-1790.
7. Guo Y, Jones D, Palmer JL, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. *Support Care Cancer*. 2014;22(5):1223-1231.
8. Desideri I, Francolini G, Becherini C, et al. Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study. *Med Oncol*. 2017 Mar;34(3):46.
9. Kim JH, Jung MH, Kim JP, et al. Alpha lipoic acid attenuates radiation-induced oral mucositis in rats. *Oncotarget*. 2017;8(42):72739-72747.
10. Shaafi S, Afrooz MR, Hajipour B, et al: Anti-oxidative effect of lipoic acid in spinal cord ischemia/reperfusion. *Med Princ Pract*. 2011;20:19-22.



Vitamin D

Vitamin D is a fat-soluble vitamin with anti-inflammatory, immunomodulatory, bone protective, and anticancer effects.

Reported anticancer benefits

Regulates genes that influence cell proliferation and apoptosis¹

Reported anticancer concerns

Toxicity, which can result in hypercalcemia¹

Evidence

People living in geographic areas with greater sun exposure (which triggers vitamin D synthesis in the human body) have lower cancer rates.²

Vitamin D helps regulate genes that influence cell proliferation, differentiation, and apoptosis.¹

Vitamin D controls immune cell regulation and differentiation, gut barrier function, and antimicrobial peptide synthesis, all of which may serve as protective factors against colon cancer.³

An inverse association between cancer and 25-hydroxyvitamin D levels is strongest for colon cancer.³⁻⁵

Several observational studies have supported an inverse association between vitamin D intake or 25-hydroxyvitamin D level and breast cancer,^{6,7} while others have not.^{8,9}

A meta-analysis reported a significant inverse association between vitamin D and breast cancer in postmenopausal women¹⁰ but not in premenopausal women.¹¹

Researchers reported a consistent prognostic association between 25-hydroxyvitamin D levels and survival in patients with colorectal cancer.¹²

Most observational studies have found that vitamin D consumption is not associated with a risk for prostate^{13,14} and ovarian cancers.¹⁵

There may be an inverse association between vitamin D supplementation and overall mortality.¹⁶ In a large prospective trial (1,260 cases vs 1,331 controls), men in the highest quartile for plasma 25-hydroxyvitamin D levels had a significantly lower risk for lethal prostate cancer than men in the lowest quartile.¹⁷

Comments

Vitamin D sufficiency is important for overall health, including cancer prevention.

Because 25-hydroxyvitamin D has a longer half-life than 1,25 dihydroxyvitamin D (15 days vs 15 hours, respectively), 25-hydroxyvitamin D is used to assess vitamin D status.¹

The bioavailability of vitamin D3 (cholecalciferol) is significantly greater than that of vitamin D-2 (ergocalciferol).¹⁸

The Dietary Reference Intakes for vitamin D were revised in 2010 and the Tolerable Upper Intake Level of vitamin D increased to 4,000 IU/d.¹

The Endocrine Society has suggested that maintenance of a 25-hydroxyvitamin D blood level of 40 to 60 ng/mL is ideal (this takes into account assay variability) and that up to 100 ng/mL is safe.¹⁹

References

1. Institute of Medicine, Food and Nutrition Board. *Dietary Reference Intakes for Calcium and Vitamin D*. National Academy Press, 2010.
2. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. *Prev Med*. 1990;19(6):614–622.
3. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. *World J Gastroenterol*. 2016;22(3):933–948.
4. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*. 2004;13(9):1502–1508.
5. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *J Clin Oncol*. 2011;29(28):3775–3582.
6. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. *Cancer Causes & Control*. 2007;18(7):775–782.
7. Yousef FM, Jacobs ET, Kang PT, et al. Vitamin D status and breast cancer in Saudi Arabian women: case-control study. *Am J Clin Nutr*. 2013;98(1):105–110.
8. Chlebowski RT, Johnson KC, Kooperberg C. Calcium plus vitamin D supplementation and the risk of breast cancer. *J Natl Cancer Inst*. 2008;100(22):1581–1591.
9. Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer—a meta-analysis. *J Ster Biochem Molec Biol*. 2008;111(3–5):195–199.
10. Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. *Medicine (Baltimore)*. 2013;92(3):123–131.
11. Wang D, Vélez de-la-Paz O, Zhai JX, Liu DW. Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. *Tumour Biol*. 2013;34(6):3509–3517.
12. Dou R, Ng K, Giovannucci EL, Manson JE, Qian ZR, Ogino S. Vitamin D and colorectal cancer: molecular, epidemiological, and clinical evidence. *Brit J Nutr*. 2016;115(9):1643–1660.
13. Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. *Am J Clin Nutr*. 2005;81(5):1147–1154.
14. Kristal AR, Arnold KB, Neuhauser ML, et al. Diet, Supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Am J Epidemiol*. 2010;172(5):566–577.
15. Qin B, Moorman PG, Alberg AJ, et al. Dairy, calcium, vitamin D and ovarian cancer risk in African-American women. *Br J Cancer*. 2016;115(9):1122–1130.
16. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. *Physiol Rev*. 2016;96(1):365–408.
17. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. *J Natl Cancer Inst*. 2012;104(9):690–699.
18. Binkley N, Gemar D, Engelke J, et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. *J Clin Endocrinol Metab*. 2011;96(4):981–988.
19. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. *Adv Exp Med Biol*. 2014;810:500–525.

Index

SAMPLE

Not for Print
or Resale

Page numbers followed by *t* indicate a table, page numbers followed by *b* indicate a box, and page numbers followed by *f* indicate a figure.

A

- AAA. *See* Acid Alkaline Association
- ABCP. *See* After Breast Cancer Pooling Project
- abdomen, normal anatomy of, 435*f*
- ABW. *See* actual body weight
- Academy of Nutrition and Dietetics, 60, 62, 67, 195–196, 290, 589, 591
- cancer survivorship, 148*b*
 - Critical Illness Evidence-Based Nutrition Practice Guideline, 83
 - end-of-life care, 556
 - esophageal cancer, 379
 - Evidence Analysis Library, 81, 504–505, 522, 548
 - Nutrition Care Process, 62–67*b*
 - Oncology Evidence-Based Nutrition Practice Guideline for Adults, 479
 - Vegetarian Nutrition, 591
- Acid Alkaline Association, 598
- acid-alkaline diet, 598–599
- ACS. *See* American Cancer Society (ACS)
- actual body weight, 83, 85
- acupressure
- mind-body intervention, 90*b*, 95
 - resources, 102*b*
- acupuncture, 89
- mind-body intervention, 90*b*, 94–95
 - resources, 102*b*
- acute kidney injury, 290
- acute lymphoblastic leukemia
- chemotherapy, 254*b*
 - hematologic malignancy, 281*f*
 - side effects, 254*b*
 - survival percentage in children, 252*f*
 - treatment, 284
 - treatment phases, 254*b*
- acute myeloid leukemia
- hematologic malignancy, 281*f*
 - survival percentage in children, 252*f*
 - treatment, 283–284
- adenocarcinoma, 13
- esophageal cancer, 375
 - lung cancer, 487, 488*f*
- Adequate Intakes (AIs), 76
- adjusted body weight, 85
- ado-trastuzumab emtansine (Kadcyla), monoclonal antibodies, 172*b*
- Adventist Health Study 2, 589
- After Breast Cancer Pooling Project (ABCP), 362, 363
- AICR. *See* American Institute for Cancer Research (AICR)
- ALA. *See* α -linoleic acid
- alcoholic beverages
- cancer prevention, 21–22
 - practice points, 21*b*
 - recommendations, 14*b*
- alemtuzumab (Campath), monoclonal antibodies, 172*b*
- algae, functional foods, 113–114
- alkaline diet, 598–599
- alkylating agents, chemotherapy, 162–164*b*
- Allium sativum* (garlic), 117, 630
- allium vegetables, prostate cancer, 517
- aloe (*Aloe barbadensis* miller), 616
- α -linolenic acid
- anti-inflammatory foods, 26
 - flaxseed and, 27
- α -lipoic acid, 618
- American Cancer Society (ACS), 1, 3, 13, 111, 135, 375, 605, 606, 609
- breast cancer, 347
 - breast cancer survivorship, 354
 - cancer survivorship, 148*b*
 - colorectal cancer, 420
 - Guideline on Diet and Physical Activity for Cancer Prevention, 582–583
 - head and neck cancers, 482
 - Nutrition and Physical Activity Guidelines for Cancer Survivors, 70
 - physical activity, 40
 - physical activity guidelines, 49
 - physical activity guidelines and cancer, 41*b*
 - practice points for cancer survivors, 24*b*
 - side effects of treatment, 185
 - vitamin D, 289
- American College of Cardiology, 47, 522
- American College of Sports Medicine, 51
- physical activity guidelines and cancer, 42*b*
 - practice points for cancer survivors, 24*b*
- American College of Surgeons, Commission on Cancer (CoC), 157
- American Heart Association, 47, 522
- American Institute for Cancer Research (AICR), 13, 111, 135, 279
- alcoholic beverages, 21
 - animal foods, 20
 - Cancer Prevention Recommendations, 584–585
 - cancer risk and body fatness, 37, 38*f*
 - cancer survivors, 23–24, 26, 148*b*, 149*b*
 - dietary supplements, 22
 - physical activity, 40
 - physical activity guidelines and cancer, 42*b*
 - predominantly plant-based diet, 17, 18*b*
 - prevention recommendations, 14–15*b*
 - red and processed meats, 19
- American Joint Committee on Cancer, 375, 517
- tumor grading system, 4*b*
- American Journal of Cancer Research*, functional foods, 115*b*

- Americans for Safe Access, cannabis use, 572*b*
- American Society for Parenteral and Enteral Nutrition, 60, 62, 67, 84, 196, 219, 225, 555*b*
 hematopoietic cell transplantation and, 316
 recommendations, 239–240
 Safe Practices for Enteral Nutrition Therapy, 230
- American Society of Clinical Oncology, 135, 354, 545
 cancer survivorship, 148*b*
 pancreatic cancer, 437
- American Thyroid Association, 534
- amino acids
 glutamine, 636
 parenteral nutrition, 235–236, 237*b*
 theanine, 658
- Amin Pharmaceutical Company, 654
- amputations
 children with, 262, 262*t*
 equations for adjusting body weight for, 265*b*
- amyloidosis, hematologic malignancies, 282, 290–291
- anal cancer, risk factors, 410–411*t*
- anal carcinoma, 405, 425–426. *See also* gastrointestinal cancers
 characteristics, 406*f*
 interventions for nutrition problems, 412–413*b*, 426
 surgery, 426
 treatment, 426
 United States statistics, 407*t*
- Anandamide, endocannabinoid, 564
- anaplastic thyroid carcinoma, 533*f*
- anastrozole (Arimidex), hormonal agents, 178–179*b*
- androgen deprivation therapy, prostate cancer, 521*b*
- anorexia and early satiety, 196
 considerations, 197*b*
 definition, 196*b*
 interventions, 197*b*
 pharmacotherapy, 197*b*
 severity grades, 197*b*
- ANS. *See* autonomic nervous system
- anthracycline antitumor antibiotics, chemotherapy, 167–168*b*
- anthropometric measurements, 40, 63*b*
- antiandrogens, hormonal agents, 178–179*b*
- antibiotics, enteral nutrition, 231*b*
- antidiarrheals, enteral nutrition, 231*b*
- antiemetics, enteral nutrition, 231*b*
- antiestrogens, hormonal agents, 178–179*b*
- anti-inflammatory foods
 antioxidant nutrients, 25
 nutrition, 25–26
 supplying omega-3 fatty acids, 26
 supporting protective microbiome, 25–26
- antimetabolites, chemotherapy, 165–166*b*
- antioxidant supplements
 breast cancer, 360, 362
 chemotherapy and, 118–119
 dietary, 118–119
 radiotherapy and, 118–119
- antitumor antibiotics, chemotherapy, 167*b*
- Anusara, yoga lineage, 98*b*
- appetite loss, prevalence in cancer patients, 547*t*
- appetite stimulants
 enteral nutrition, 231*b*
 pediatric oncology, 269*b*
- aromatase inhibitor-induced musculoskeletal symptoms, breast cancer, 351
- aromatase inhibitors, hormonal agents, 178–179*b*
- artificial hydration
 decision for use, 556–557
 palliative care, 553, 556
- artificial nutrition
 decision for use, 556–557
 guidelines for patients with advanced cancer, 554–555*b*
 palliative care, 553, 554–555*b*
- ascites, medical nutrition therapy, 453–454
- ascitic fluid, patients with hepatic compromise, 417*b*
- Ashtanga, yoga lineage, 98*b*
- ASPEN. *See* American Society for Parenteral and Enteral Nutrition
- Aspergillus* inhalation, 570
- Aspiration, enteral nutrition therapy, 228*b*
- assessment parameters, pediatric oncology patients, 263–264*b*
- assessment tools, gynecologic cancers, 504–505
- astrocytoma, category and nutrition, 255*b*
- atypical teratoid/rhabdoid tumor, category and nutrition, 255*b*
- autonomic nervous system, 92, 93*f*, 99
- axillary lymph node dissection, breast cancer, 349
- Ayurveda, 91, 102*b*
- azacitidine (Vidaza), chemotherapy agent, 165*b*
- azotemia, parenteral nutrition, 243*b*

B

- Bacteroides fragilis*, colorectal cancer, 421
- basal energy expenditure, 81*b*
- basal metabolic rate, 81*b*
- BEE. *See* basal energy expenditure
- bendamustine (Treanda), chemotherapy agent, 162*b*
- β carotene, dietary supplement, 22, 116
- bevacizumab (Avastin), angiogenesis inhibitors, 175*b*
- beverages
 alcoholic, 21–22
 sugar-sweetened, 20–21
- Bhajan, Yogi, 98*b*
- bicalutamide (Casodex), hormonal agents, 178–179*b*
- Bikram, yoga lineage, 98*b*
- bile duct, 442*f*, 443*f*, 444*f*, 445*f*
 cholangiocarcinoma, 436
 obstructed, 446
 sample PES statements of cancers, 462
 symptoms of blocked, 447*b*
- bile reflux gastritis, postgastrectomy, 393*b*
- Bill Henderson protocol, 600–601
- Billroth I/II, gastrectomy, 384, 385*f*, 386

- bioelectrical impedance, 132
- bioimpedance analysis (BIA), 40
- bisphenol A, 5
- black cohosh (*Cimicifuga racemosa*), 620
- Black Women's Health Study, breast cancer, 355
- blenderized tube feedings, enteral nutrition, 222, 223–224*b*
- bleomycin (Blenoxane), chemotherapy agent, 167*b*
- blood work, pancreatic cancer survivors, 458, 459*b*
- BMI. *See* body mass index
- BMR. *See* basal metabolic rate
- body composition changes, cancer and, 76
- body fatness, evidence for cancer risk and, 38*f*
- body mass index (BMI), 14*b*
- anthropometric measures, 40, 63*b*
 - breast cancer, 350
 - cachexia and, 45
 - cancer diagnosis, 46–47
 - cancer risk, 37
 - complementary and alternative medicine (CAM) and, 92
 - head and neck cancers, 479
 - hematologic malignancies, 279–280, 291–292
 - hematopoietic cell transplantation and, 312, 314
 - hospice patients, 548–549
 - lung cancer, 491
 - sarcopenia and, 45
 - term, 81*b*
 - weight-related risk, 15–16, 16*b*
- body surface area (BSA) method, hydration, 78
- body weight
- estimating energy needs, 84*t*
 - hematopoietic cell transplantation and, 312–313
 - prostate cancer, 520
- bone density, pancreatic cancer, 458–459
- bone disease
- after gastrectomy, 394*b*
 - hematopoietic cell transplantation, 321
- bone health, hematologic malignancies, 287–288
- bone loss
- breast cancer, 351–352
 - prostate cancer, 521*b*
- bone mineral density, pancreatic cancer survivors, 458, 459*b*
- bone tumor, distribution of
- childhood cancer, 251*f*
- bortezomib (Velcade), protein-targeted agent, 174*b*
- bowel management
- colorectal cancer, 424
 - gastrointestinal cancers, 413*b*
- brachytherapy, 183, 185
- general placement types, 188*b*
 - high-dose rate, 189*b*
 - low-dose rate, 189*b*
 - permanent, 189*b*
 - pulsed-dose-rate, 189*b*
 - side effects of, 190*b*
 - temporary, 189*b*
 - types by duration, 189*b*
- brain, major parts of, 332*f*
- brain cancer, term, 331
- brain stem, 332*f*
- brainstem glioma, category and nutrition, 255*b*
- brain tumor
- caregiver support, 337, 340, 341*b*
 - hyperglycemia, 333–334
 - incidence and diagnosis, 331, 333
 - ketogenic diet, 335–337
 - mealtime strategies, 340, 341*b*
 - metastatic, 331
 - nutrition assessment, 333
 - nutrition impact symptoms, 334*b*
 - risk factors, 331
 - sample PES statements, 342
 - survivorship, 337, 340
 - term, 331
 - treatment, 333
- breast cancer, 347
- alcohol, 21
 - animal foods, 20
 - antioxidant supplements, 360, 362
 - aromatase inhibitor-induced musculoskeletal symptoms, 351
 - bone loss, 351–352
 - carotenoids, 356
 - chemotherapy-induced nausea and vomiting, 352
 - dairy, 357–358
 - dietary supplements, 360, 362–364
 - ductal carcinoma in situ (DCIS), 347, 348*f*
 - endocrine, targeted and maintenance therapy, 350*b*
 - fasting, 360
 - fasting during treatment, 353
 - fatigue, 350
 - food advice, 361*b*
 - fruits, vegetables, and fiber, 355–356
 - lifestyle advice, 354, 361*b*
 - lignans, 356
 - low-fat diet, 354–355
 - lymphedema, 350–351
 - mucositis, 352–353
 - multivitamin and mineral supplements, 362
 - neuropathy, 352
 - nutrition assessment, 349–350
 - nutrition-related side effects and interventions, 128*b*
 - omega-3 fatty acids, 358, 359*t*
 - omega-3 fatty acid supplements, 363–364
 - physical activity and, 50
 - prognosis, 347
 - prognostic biomarkers, 347
 - red meat, 358
 - risk factors for, 347*b*
 - sample PES statements for, 364
 - soy, 356–357, 357*t*
 - surgery, 349
 - survival, 23–24
 - systemic therapy, 349
 - taste changes, 353
 - treatment, 349
 - type of, 348*f*
 - vasomotor symptoms, 351
 - vitamin D supplements, 362–363
 - weight and risk, 358–359
 - weight gain during treatment, 353–354
 - weight-loss interventions, 359–360
- Breast Cancer Weight Loss (BWEL), 144–145*t*

breast-conserving surgery, breast cancer, 349
breastfeeding
 lactation and, 23
 practice points for, 23*b*
Brown, Michael S., 603
Budwig, Johanna, 602
Budwig diet, 600, 602–603
busulfan (Busulfex), chemotherapy agent, 162*b*
busulfan (Myleran), chemotherapy agent, 162*b*

C

cachexia
 identifying cancer, 61–62
 inflammation, 75
 lung cancer, 494
 sarcopenic obesity and, 44–46
 stages of cancer, 45*f*
calcium
 breast cancer, 351–352
 dietary supplement, 22
 osteoporosis, 292–293
 ovarian cancer, 500
 pediatric cancer patients, 267, 268*t*
 prostate cancer, 519–520, 524*b*
California Department of Health Services, 609
California Teachers Study, 589
Camellia sinensis (green tea), 638
Canadian Foundation for Dietetic Research, functional foods, 115*b*
cancer. *See also* childhood cancer;
 hematologic malignancies
 alcoholic beverages, 21–22
 body composition changes with, 76
 common types in US, 1*t*
 cost of care, 1–2
 dietary supplements and, 114–119
 functional foods and, 111–114
 metabolic changes in, 75
 nutrition concerns and outcomes, 8*b*, 9*b*
 nutrition-related side effects and interventions, 128–131*b*

 screening, 2–3
 staging, 3–4
 survival rates by race, 2*f*
 survivorship, 148*b*
 term, 1
cancer cachexia
 definition, 61
 identifying, 61–62
 stages of, 45*f*
Cancer Council of Australia, 479
Cancer Exercise Trainer, 51
cancer patients
 efficacy of cannabis use by, 565–568
 functional foods in care process, 114
 malnutrition and, 59
 navigating dietary supplements, 119
 palliative care, 546–548
 prevalence of nutrition-related symptoms, 547*t*
 refeeding syndrome, 85
cancer prevention
 adiposity and weight gain, 13, 15–16
 alcoholic beverages, 21–22
 American Cancer Society on diet and physical activity, 582–583
 anti-inflammatory foods, 25–26
 dietary supplements, 22–23
 flaxseed, 27–28
 foods promoting weight gain, 19
 genetically engineered foods, 25
 lactation and breastfeeding, 23
 organic foods, 24–25
 physical activity, 16–17
 physical activity guidelines, 41–43*b*
 predominantly plant-based diet, 17–19
 recommendations for, 13, 14–15*b*
 red and processed meats, 19–20
 soy foods, 26–27
 sugar-sweetened beverages, 20–21
World Cancer Research Fund/American Institute for Cancer Research recommendations, 584–585

Cancer Prevention Study II, 279, 354
cancer risk
 energy restriction and, 39–40
 evidence for body fatness and, 38*f*
 intentional weight loss and, 39
 obesity, weight gain and, 37, 39
 physical activity and, 40
Cancer Survival Through Lifestyle Change (CASTLE), 138–139*t*
cancer survivors
 breast cancer, 23–24, 27–28
 clinically-based supervised programs, 136–137*t*
 commercial programs, 140–141*t*
 community-based programs, 140–141*t*
 dietary intervention and physical activity, 136–143*t*
 dietary intervention trials, 144–145*t*
 dietary patterns and quality, 135, 146–147
 efficacy of cannabis use by, 565–568
 excess adiposity during, 46–47
 flaxseed and, 27–28
 home-based programs, 142–143*t*
 lifestyle interventions, 134*f*
 managing symptoms early posttreatment, 127, 132
 medical nutrition therapy (MNT), 133, 135
 mixed-modality programs, 138–139*t*
 nutritional assessment of, 132–135
 nutritional resources for, 147, 148–149*b*
 nutrition-related side effects and interventions, 128–131*b*
 physical activity guidelines, 41–43*b*
 post-symptom diet therapy, 133
 practice points for, 24*b*
 role of physical activity and lean mass, 147
 soy and breast cancer, 26–27
 technology-based programs, 142–143*t*

- telephone counseling, 138–141*t*
 - term, 23, 127
 - weight management for, 47, 48–49*b*
- cancer survivorship, 127
 - brain tumor, 337, 340
 - breast cancer, 354–364
 - esophageal cancer, 381–382
 - gastric cancer, 389
 - gynecologic cancers, 508
 - head and neck cancers, 482*b*, 482–483
 - hematologic malignancies, 292–293
 - hematopoietic cell transplantation, 321, 323
 - long-term, 50–51
 - lung cancer, 494
 - pancreatic cancer, 458–459, 459*b*, 460–461*b*
 - physical activity and, 49–51
 - prostate cancer, 522, 523–524*b*
- cancer treatment. *See also* chemotherapy; nutrition impact symptoms
 - cancer-specific factors affecting response to, 158*b*
 - conventional modalities of, 158*f*
 - excess adiposity during, 46–47
 - hormone therapy, 177, 178–179*b*
 - immunotherapy, 171, 176–177
 - personalized medicine, 161, 170
 - physical activity during, 49–50
 - posttreatment nutrition, 7
 - role of nutrition in, 6–7, 8–9*b*
 - targeted therapy, 170–171
 - vaccines, 177
 - weight management in, 70
- CanChange, 144–145*t*
- cannabidiol, 563
- cannabidiolic acid, 563
- cannabis
 - adverse effects, 570, 571*b*
 - cannabidiol (CBD) in, 563
 - cannabinoid medicines, 564–565
 - cannabinoids, 564
 - chemical variety, 563
 - chemotherapy-induced nausea and vomiting, 566
 - coadministration of THC and CBD, 567
 - contraindications, 569*b*, 569–570
 - counseling on, 572
 - drug interactions, 570, 571*b*
 - efficacy of use by cancer patients and survivors, 565–568
 - endocannabinoid system, 564
 - medicinal use of, 563–564, 573
 - pharmacokinetics, 568*t*, 568–569
 - plant in Cannabaceae family, 563
 - precautions for use, 569*b*
 - resources relating to use, 572*b*
 - safety concerns, 570–572
 - terpenoids in, 565*b*
 - tetrahydrocannabinol (THC) in, 563, 564–567
- capecitabine (Xeloda), chemotherapy agent, 165*b*
- Capital Health Home Parenteral Nutrition Program Edmonton, 554*b*
- carbohydrates
 - Dietary Reference Intake (DRI), 77–78, 78*t*
 - metabolism, 75*b*
 - requirements during hematopoietic cell transplantation, 311*b*
- carboplatin (Paraplatin), chemotherapy agent, 162*b*
- carcinogenesis, 4, 5
 - effects of functional foods on, 112
 - nutrition and, 4, 5
 - possible effects of nutrients on stages of, 5*f*
- carcinoid syndrome, neuroendocrine tumors of small bowel, 419–420
- cardiometabolic changes, hematopoietic cell transplantation, 321, 323
- cardiovascular events, hematologic malignancies, 292
- caregivers
 - brain tumor, 337, 340, 341*b*
 - head and neck cancers, 481*b*
- carmustine, chemotherapy agent, 162*b*
- carotenoids, 18, 356
- CASTLE. *See* Cancer Survival Through Lifestyle Change
- CBDA. *See* cannabidiolic acid
- CDC. *See* Centers for Disease Control and Prevention
- Centers for Disease Control and Prevention (CDC)
 - breastfeeding, 23*b*
 - cancer survivorship, 148*b*
 - dietary supplements, 116
- central nervous system tumors
 - astrocytoma, 255*b*
 - brainstem glioma, 255*b*
 - craniopharyngioma, 256*b*
 - distribution, 251*f*
 - embryonal tumor, 255*b*
 - ependymoma, 256*b*
 - germ cell tumor, 256*b*
 - medulloblastoma, 255*b*
 - nutrition impact symptoms, 253, 255–256*b*
- cerebellum, 332*f*
- cerebrum, 332*f*
- certified specialists in oncology nutrition, 23
- Cervarix, recombinant HPV bivalent vaccine, 177
- cervical cancer, 500, 502. *See also* gynecologic cancers
 - diagnosis, 502
 - risk and protective factors, 501*b*
 - site and type, 503*f*
 - treatment, 504
 - United States statistics, 499*t*
- cetuximab (Erbixux), monoclonal antibodies, 172*b*
- chemotherapy, 157, 158*f*, 160–161
 - acute lymphoblastic leukemia, 284
 - acute myeloid leukemia, 283
 - administration of, 160
 - agents in, 160
 - alkylating agents for, 162–164*b*
 - anthracycline antitumor antibiotics, 167–168*b*
 - antimetabolites for, 165–166*b*
 - antioxidant supplements and, 118–119
 - antitumor antibiotics for, 167*b*
 - cancer treatment, 6–7
 - chronic lymphocytic leukemia, 284

- chronic myeloid leukemia, 284
- conditioning regimens, 306, 307*f*
- epipodophyllotoxins, 168*b*
- Hodgkin lymphoma, 285
- lung cancer, 489–490
- modes of action, 160
- nausea and vomiting induced by, 287
- non-Hodgkin lymphoma, 284–285
- nutritional implications, 160–161, 162–169*b*
- pancreatic adenocarcinoma, 438*b*
- side effects of, 7, 160–161, 162–169*b*
- taxanes for, 169*b*
- vinca alkaloids, 169*b*
- chemotherapy-induced nausea and vomiting, 287, 352
- medical cannabis and, 566
- chemotherapy-induced peripheral neuropathy, 50, 352
- chemovar, cannabis, 563
- chicory root, functional foods, 113
- childhood cancer. *See also* nutrition assessment in childhood cancer
- acute lymphoblastic leukemia, 253, 254*b*
- acute myeloid leukemia, 253
- central nervous system tumors, 253, 255–256*b*
- children with amputations, 262, 262*t*, 265*b*
- chimeric antigen receptor (CAR) T-cell therapy, 258
- distribution of diagnoses in US, 251*f*
- Ewing sarcoma, 258
- hepatoblastoma, 258
- Hodgkin lymphoma, 253, 256
- hyperthermic intraperitoneal chemotherapy (HIPEC), 258
- malnutrition prevalence and outcomes, 259, 259*b*, 260*t*
- neuroblastoma, 257
- non-Hodgkin lymphoma, 256–257
- nutrition assessment, 262, 266–268
- nutrition impact symptoms and, 252–258
- nutrition interventions and support, 268–270
- nutrition screening, 260–261, 261*f*
- osteosarcoma, 258
- resources, 253*b*
- rhabdomyosarcoma, 257
- survival by diagnosis, 252*f*
- survivors of, 252
- Wilms tumor, 257
- Children's Oncology Group, 252, 253*b*
- chimeric antigen receptor (CAR) T-cell therapy, 177, 258, 285
- hematologic malignancies, 323
- non-Hodgkin lymphoma, 285
- China's *Pen Ts'ao Ching*, 563
- chlorambucil (Leukeran), chemotherapy agent, 163*b*
- CHOICE Study, 136–137*t*
- cholangiocarcinoma, 405. *See also* gastrointestinal cancers
- biliary system, 417*f*
- characteristics, 406*f*
- distal cholangiocarcinoma (dCCA), 417*f*
- interventions and nutrition, 415, 418
- interventions for nutrition problems, 412–413*b*, 421, 424–425
- intrahepatic cholangiocarcinoma (iCCA), 417*f*
- palliative interventions, 415
- perihilar cholangiocarcinoma (pCCA), 417*f*
- risk factors, 408–409*t*
- surgery, 415
- treatment, 415
- types, 417*f*
- United States statistics, 407*t*
- cholestasis, parenteral nutrition, 244*b*
- choline, prostate cancer, 520
- Choudhury, Bikram, 98*b*
- chronic kidney disease, 290
- chronic lymphocytic leukemia
- hematologic malignancy, 281*f*
- treatment, 284
- chronic myeloid leukemia
- hematologic malignancy, 281*f*
- treatment, 284
- chyle leak, medical nutrition therapy, 458
- Cimicifuga racemosa* (black cohosh), 620
- CIPN. *See* chemotherapy-induced peripheral neuropathy
- cisplatin (Platinol, CDDP), chemotherapy agent, 163*b*
- classification system, tumor, lymph node, metastasis (TNM), 3*b*
- Clinical Oncological Society of Australia, 196
- Clostridium difficile*, 268
- colorectal cancer, 421
- hematopoietic cell transplantation, 315
- Cochrane Collaboration, 96, 99, 101
- Cocinar Para Su Salud, 140–141*t*
- coenzyme Q10 (CoQ10), 362, 622
- colorectal cancer, 405
- animal foods, 20
- bowel management, 424
- characteristics, 406*f*
- cytoreductive surgery, 421
- hyperthermic intraperitoneal chemotherapy, 421
- incidence, 420
- interventions for nutrition problems, 412–413*b*, 421, 424–425
- low anterior resection syndrome, 424–425
- neorectal reservoirs, 425
- nutrition-related side effects and interventions, 129*b*
- ostomy management, 424
- red and processed meat, 19–20
- risk factors, 410–411*t*
- surgery, 421, 422–423*f*
- treatment, 421
- United States statistics, 407*t*
- vitamin and mineral malabsorption, 425
- colorectal cancers. *See* gastrointestinal cancers
- Common Terminology Criteria for Adverse Events, 195
- anorexia and early satiety, 196, 196–197*b*
- constipation, 196, 200–201*b*
- diarrhea, 196, 202–203*b*
- dysphagia, 196, 204–205*b*

- fatigue, 196, 206–207*b*
grading system, 196*b*
malabsorption, 196, 208–209*b*
nausea and vomiting, 196,
210–211*b*
oral candidiasis, 196, 214*b*
oral mucositis and esophagitis,
196, 212–213*b*
taste and smell changes, 196,
197–198*b*
xerostomia, 196, 215*b*
- complementary and alternative
medicine (CAM)
in cancer treatment and
survivorship, 91–92
motivators, 91–92
practical applications, 100–101
prevalence of, 91
resources, 102*b*
term, 89
- computed tomography, 40
imaging, 41–43
nutrition assessment, 132
- conditioning regimens
chemotherapy, 306
dose intensities, 307*f*
side effects, 306
- consolidation therapy
acute lymphoblastic leukemia,
284
acute myeloid leukemia,
283–284
- constipation
definition, 200*b*
enteral nutrition therapy, 229*b*
interventions, 201*b*
pharmacotherapy, 201*b*
prevalence in cancer patients,
547*t*
severity grades, 200*b*
- contralateral prophylactic
mastectomy, breast cancer, 349
- Controlled Substances Act (1970),
563
- copper, pancreatic cancer survivors,
461*b*
- Coriolus versicolor*, 660
- counseling, cannabis, 572
- craniopharyngioma, category and
nutrition, 256*b*
- crizotinib (Xalkori), protein-
targeted agent, 174*b*
- cruciferous vegetables
prostate cancer, 517, 523*b*
thyroid cancer, 532
- CSOs. *See* certified specialists in
oncology nutrition
- CT. *See* computed tomography
- CTCAE. *See* Common Terminology
Criteria for Adverse Events
- curcumin (*Curcuma longa*), 624
- Curves, 140–141*t*
- cyclophosphamide (Cytosan,
CTX), chemotherapy agent, 163*b*
- cyproheptadine (Periactin),
pediatric oncology, 269*b*
- cytarabine (ARA-C), chemotherapy
agent, 165*b*
- cytochrome P-450, enzyme system,
17, 117
- cytomegalovirus, hematopoietic cell
transplantation, 315
- cytoreductive surgery, colorectal
cancer, 421
- ## D
- dacarbazine (DTIC), chemotherapy
agent, 163*b*
- dactinomycin (Actinomycin D),
chemotherapy agent, 167*b*
- dairy
breast cancer, 357–358
prostate cancer, 519–520, 523*b*
- dasatinib (Sypricel), protein-
targeted agent, 174*b*
- Daughters and MothErS Against
Breast Cancer (DAMES), 142–
143*t*
- daunorubicin (Daunomycin),
chemotherapy agent, 167*b*
- dehydration, enteral nutrition
therapy, 226*b*
- delayed gastric emptying
medical nutrition therapy, 456
nutrition support, 455
surgeries for pancreatic cancer,
441*b*
- denosumab (Prolia), monoclonal
antibodies, 173*b*
- denosumab (Xgeva), monoclonal
antibodies, 173*b*
- Desai, Yogi Amrit, 98*b*
- Desikachar, T. K. V., 98*b*
- dextrose, parenteral nutrition,
235–236, 237*b*
- DHA. *See* docosahexaenoic acid
(DHA)
- diabetes mellitus
pancreatic cancer, 452–453
surgeries for pancreatic cancer,
441*b*
- diarrhea
considerations, 202*b*
definition, 202*b*
enteral nutrition therapy,
228–229*b*
interventions, 203*b*
intestinal transit-inhibiting
medications, 457*t*
medical nutrition therapy,
456–457
neuroendocrine tumors of small
bowel, 420
pharmacotherapy, 203*b*
prevalence in cancer patients,
547*t*
radiation-induced, in
gynecologic cancers, 505–
506
severity grades, 202*b*
- Dietary Approaches to Stop
Hypertension, 331
- Dietary Guidelines Advisory
Committee, 581
- Dietary Guidelines for Americans,*
2020–2025, 9th Edition, 13,
580–581
Healthy Mediterranean-Style
Diet, 586–587
Healthy Vegetarian Diet,
588–589
- dietary patterns, energy restriction,
46*b*
- Dietary Reference Intakes (DRIs),
76–79, 662
carbohydrates, 77, 78*t*
fats, 77, 78*t*
fluid requirements, 78, 79*t*
macronutrient needs, 77–78,
78*t*
micronutrient needs, 79, 80*b*
protein, 77, 77*t*, 78*t*
- Dietary Supplement Health and
Education Act (1994), 115, 116

- dietary supplements. *See also* diets;
 diets (alternative and unfounded)
 antioxidants, 118–119, 360, 362
 β carotene, 22
 breast cancer, 360, 362–364
 calcium, 22
 cancer and, 114–119
 cancer prevention, 22–23
 cancer survivors, 147
 coenzyme Q10, 362
 multivitamin and mineral
 supplements, 362
 navigating, 119
 omega-3 fatty acids, 363–364
 plants and pharmaceuticals, 117
 practice points for, 22*b*
 prevalence, 116
 prostate cancer, 520
 resources, 120*b*
 safety, 116
 selenium, 22
 vitamin D, 22, 362–363, 662
 vitamin E, 22
 vitamin-mineral, 117–118
- dietary supplements/functional
 foods
 aloe (*Aloe barbadensis miller*),
 616
 α-lipoic acid, 618
 black cohosh (*Cimicifuga
 racemosa*), 620
 coenzyme Q10 (CoQ10), 622
 curcumin (*Curcuma longa*),
 624
 3,3'-diindolylmethane (DIM)
 and indole-3-carbinol (I3C),
 626
 flaxseed (*Linum usitatissimum*),
 628
 garlic (*Allium sativum*), 117,
 630
 ginger (*Zingiber officinale*), 632
Ginkgo biloba, 634
 glutamine, 636
 green tea (*Camellia sinensis*),
 638
 melatonin, 640
 N-acetylcysteine (INAC), 642
 omega-3 fatty acids, 644
 quercetin, 646
 reishi mushroom (*Ganoderma
 lucidum*), 648
 resveratrol, 650
 St. John's wort (*Hypericum
 perforatum*), 656
 selenium, 652
 silymarin (*Silybum marianum*),
 654
 theanine, 658
 turkey tail mushroom or Yun
 Zhi, 660
 vitamin D, 662
- diets. *See also* diets (alternative and
 unfounded)
 American Cancer Society
 guideline, 582–583
 cancer prevention
 recommendations (World
 Cancer Research Fund/
 American Institute for
 Cancer Research), 584–585
 guidelines, 580–581
 Healthy Mediterranean-Style
 Diet, 586–587
 Healthy Vegetarian Diet,
 588–589
 Intermittent Fasting, 592–593
 Ketogenic Diet, 594–595
 modification for pancreatic
 exocrine insufficiency, 452
 Vegan Diet, 590–591
- diets (alternative and unfounded)
 alkaline diet, 598–599
 Bill Henderson protocol,
 600–601
 Budwig diet, 602–603
 Gerson Therapy, 604–605
 Gonzalez regimen, 606
 Livingston-Wheeler therapy,
 608–609
 macrobiotic diet, 610–611
 raw food plan, 612–613
 diffuse large B-cell lymphoma, 279,
 280, 281*f*
 dihydropyrimidine dehydrogenase
 (DPD), 161
 3,3'-diindolylmethane (DIM), 626
 distal pancreatectomy, 441*b*, 445*f*,
 445*f*. *See also* pancreatic cancer
 DNA damage, carcinogenesis, 4, 5
 docetaxel (Taxotere), chemotherapy
 agent, 169*b*
 docosahexaenoic acid (DHA)
 anti-inflammatory foods, 26
 breast cancer, 358
 functional foods, 114, 644
 seafood content, 359*t*
 doxorubicin (Adriamycin),
 chemotherapy agent, 167*b*
 doxorubicin liposomal (Doxil),
 chemotherapy agent, 168*b*
 DRIs. *See* Dietary Reference
 Intakes
 dronabinol, 564
 cannabinoids, 564–565
 pediatric oncology, 269*b*
 dual-energy x-ray absorptiometry,
 40, 132
 ductal carcinoma in situ (DCIS),
 347, 348*f*. *See also* breast cancer
 dumping syndrome
 definition, 381*b*
 esophageal cancer, 380, 381*b*
 medical nutrition therapy, 381*b*
 postgastrectomy, 391–392*b*
 surgeries for pancreatic cancer,
 441*b*
 durable medical equipment, 233
 DXA. *See* dual-energy x-ray
 absorptiometry
 dysgeusia, prevalence in cancer
 patients, 547*t*
 dysphagia
 considerations, 204*b*
 definition, 204*b*
 esophageal cancer, 379
 head and neck cancers, 480
 interventions, 205*b*
 pharmacotherapy, 205*b*
 prevalence in cancer patients,
 547*t*
 severity grades, 204*b*
 thyroid cancer, 539
 Dysphagia Grading Score, 388
- ## E
- EACs. *See* esophageal
 adenocarcinomas
 early satiety
 anorexia and, 196, 196–197*b*
 postgastrectomy, 390*b*
 prevalence in cancer patients,
 547*t*

- EBRT. *See* external beam radiation therapy
- Echinacea purpurea (echinacea), 117
- EEE. *See* estimated energy expenditure
- EER. *See* estimated energy requirement
- eggs, 20
- prostate cancer, 520, 523*b*
- eicosapentaenoic acid (EPA)
- anti-inflammatory foods, 26
 - breast cancer, 358
 - functional foods, 114, 644
 - seafood content, 359*t*
- electrolytes
- derangements of, and parenteral nutrition, 243*b*
 - parenteral nutrition, 235–236, 238, 238*b*
 - requirements during hematopoietic cell transplantation, 312*b*
- electronic medical record, 60
- embryonal tumors, category and nutrition, 255*b*
- Endocrine Society, 662
- endocrine therapy
- breast cancer, 349
 - vitamin D, 289
- end-of-life care, parenteral nutrition, 245. *See also* hospice; palliative care
- endometrial cancer, 499, 500
- diagnosis, 502
 - risk and protective factors, 501*b*
- energetics
- anthropometric measures, 40
 - biological mechanisms of cancer and, 43–44
 - direct measures, 40–43
- ENERGY. *See* Exercise and Nutrition to Enhance Recovery and Good Health for You study
- energy needs
- body weight, 85
 - body weight estimating, 84*t*
 - decision tree for predictive equation, 82*f*
 - equations for critically ill population, 83–84
 - equations for noncritically ill population, 83
- estimating, 79–85
- expenditure terminology, 81*b*
- gynecologic cancers, 505
- hematopoietic cell transplantation, 310*b*
- indirect calorimetry (IC), 80–81
- Mifflin-St. Jeor equation, 82*f*, 83
- obese population
- considerations, 84–85
- older adult population
- considerations, 85
- pancreaticoduodenectomy, 454
- patients with hepatic compromise, 416*b*
- Penn State equations, 82*f*, 84
- predictive equations, 81, 83–85
- weight-based equation, 84
- energy restriction
- cancer risk and, 39–40, 46
 - dietary patterns, 46*b*
- enhanced recovery after surgery, 386, 412*b*
- enteral access device, 220, 221*b*
- alternative medication for use in, 231–232*b*
 - managing clogged, 230, 230*b*
- enteral nutrition, 219–220, 222–223. *See also* parenteral nutrition access devices, 220, 221*b* administration of, 222–223, 225*t*
- blenderized tube feedings, 222
 - contraindications to, 220
 - esophageal cancer, 379
 - formulations, 220, 222, 223–224*b*
 - gastric cancer, 387, 387*b*
 - gastrointestinal cancers, 412*b*, 413*b*
 - gastrointestinal complications, 225, 228–229*b*
 - guidelines for patients with advanced cancer, 554–555*b*
 - head and neck cancers, 482
 - hematopoietic cell transplantation, 316, 318, 319
 - home regimens, 233–234
 - indications for, 219, 220*b*
 - initiation and advancement of feedings, 222–223, 225*t*
 - insurance considerations, 233
- mechanical and microbial complications, 230, 230*b*
- medication administration, 230, 231–232*b*
- metabolic complications of, 223, 225, 226–227*b*
- modular nutrients, 223–224*b*
- for oncology population, 219–220
- pancreatic exocrine insufficiency, 451
 - patient safety, 230, 232–233
- enterocutaneous fistulas, gastrointestinal cancers, 413*b*
- EPA. *See* eicosapentaenoic acid (EPA); US Environmental Protection Agency
- ependymoma, category and nutrition, 256*b*
- EPI. *See* exocrine pancreatic insufficiency
- epigallothechin-3-gallate (EGCG), 638
- epipodophyllotoxins, chemotherapy, 168*b*
- epirubicin (Ellence), chemotherapy agent, 168*b*
- erlotinib (Tarceva), protein-targeted agent, 174*b*
- ESCCs. *See* esophageal squamous cell carcinomas
- Escherichia coli*, colorectal cancer, 421
- esophageal cancer
- adenocarcinomas, 375, 376*b*
 - diagnosis, 375
 - diet recommendations for stent patients, 377*b*
 - dumping syndrome, 380, 381*b*
 - dysphagia, 379
 - early oral feeding after surgery, 380
 - esophageal stents, 377
 - esophagectomy, 375, 377, 378*f*
 - malnutrition, 379
 - nutrition assessment in patients, 377
 - nutrition impact symptoms, 376*b*, 377
 - nutrition support, 379
 - postoperative nutrition, 379–380

- postoperative nutrition
 complications, 380–381
 prevalence and risk factors, 376*b*
 sample PES statements, 395
 squamous cell carcinomas, 375, 376*b*
 surgery, 375, 377
 survivorship and, 381–382
 treatment, 375, 376*b*, 377
 types of, 375
 weight loss and sarcopenia, 379
- esophagitis
 considerations, 212–213*b*
 definition, 212*b*
 interventions, 213*b*
 pharmacotherapy, 213*b*
 severity grades, 212*b*
- ESPEN. *See* European Society for Clinical Nutrition and Metabolism
- essential fatty acid deficiency, parenteral nutrition, 242*b*
- estimated energy expenditure, 81*b*
- estimated energy requirement, 81*b*
- estrogen, obesity and cancer, 44
- etoposide (Vepesid, VP-16), chemotherapy agent, 168*b*
- European Prospective Investigation into Cancer and Nutrition, 331, 354, 355
- European Society for Clinical Nutrition and Metabolism, 60, 75, 76, 288, 380
 guidelines for patients with advanced cancer, 555*b*
 Guidelines on Nutrition for Cancer Patients, 76, 77
 hematopoietic cell transplantation and, 316
 nutrition support, 454
- everolimus (Affinitor), protein-targeted agent, 174*b*
- Evidence Analysis Library Oncology Workgroup, 61
- Ewing sarcoma, nutrition side effects, 258
- exemestane (Aromasin), hormonal agents, 178–179*b*
- Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) study, 138–139*t*, 360
- exocrine pancreatic insufficiency, 380–381, 439
- external beam radiation therapy, 183
 dosage, 185
 image-guided radiation therapy (IGRT), 184
 intensity-modulated radiation therapy (IMRT), 184
 intraoperative radiation therapy (IORT), 184–185
 side effects, 185, 186*f*, 187*b*, 188*b*
 stereotactic radiation therapy (SRT), 184
 stereotactic radiosurgery (SRS), 184
 three-dimensional conformal radiation therapy (3D-CRT), 184
 total body irradiation (TBI), 184
 uterine cancer, 502
- F**
- fasting, breast cancer treatment and, 353
- fat consumption, prostate cancer, 519
- fatigue
 breast cancer, 350
 considerations, 206*b*
 definition, 206*b*
 interventions, 207*b*
 pharmacotherapy, 207*b*
 severity grades, 206*b*
- fat malabsorption, after gastrectomy, 395*b*
- fats
 Dietary Reference Intake (DRI), 77–78, 78*t*
 requirements during hematopoietic cell transplantation, 311*b*
- FDA. *See* US Food and Drug Administration
- Federal Trade Commission, 116
- fish
 consumption, 20
 prostate cancer, 523*b*
- Fit4Life, 142–143*t*
- FITT (frequency, intensity, time and type) principle, 51
- flaxseed (*Linum usitatissimum*), 628
 breast cancer, 356
 cancer survivors and, 27–28
 functional foods, 113
 nutrition, 27
 prostate cancer, 524*b*
- fludarabine (Fludara), chemotherapy agent, 165*b*
- fluid requirements, 78, 79*t*
 estimating needs for pediatric cancer patients, 267, 267*b*
 hematopoietic cell transplantation, 312*b*
- fluorouracil (5-FU), chemotherapy agent, 5, 161, 165*b*
- flutamide (Eulexin), hormonal agents, 178–179*b*
- focused attention, 96
- folate deficiency, after gastrectomy, 394*b*
- follicular thyroid carcinoma, 533*f*
- food advice, breast cancer, 354–358, 361*b*
- Food and Agriculture Organization of the United Nations, 491
- Frankenfield, David, 84
- French National Federation of Cancer Centers, 554*b*
- French Nutrition Oncology Study Group, 549
- FRESH START, 144–145*t*
- functional foods. *See also* dietary supplements/functional foods
 cancer and, 111–114
 definition of, 111–112
 effects on carcinogenesis, 112
 examples and evidence for, 112–114
 incorporating in cancer Nutrition Care Process, 114
 regulation of, 114
 resources, 115*b*
- G**
- gallbladder carcinoma, 405. *See also* gastrointestinal cancers

- characteristics, 406*f*
- interventions for nutrition
 - problems, 412–413*b*, 418
 - risk factors, 408–409*t*
 - treatment, 418
 - United States statistics, 407*t*
- gallbladder sludge/stones,
 - parenteral nutrition, 244*b*
- Ganoderma lucidum* (reishi mushroom), 648
- Gardasil, recombinant HPV quadrivalent vaccine, 177
- garlic (*Allium sativum*), 117, 630
- gastrectomy
 - nutrient deficiencies and conditions, 394–395*b*
 - reconstruction types, 384, 385*f*, 386
- gastric cancer
 - bile reflux gastritis, 393*b*
 - diagnosis of, 382, 384
 - dumping syndrome, 391*bA*–392*b*
 - early satiety syndrome, 390*b*
 - gastric stasis, 390–391*b*
 - normal anatomy of stomach, 383*f*
 - nutrient deficiencies after gastrectomy, 394–395*b*
 - nutrition impact symptoms, 386
 - nutrition support, 387, 387*b*
 - palliative nutrition management, 388–389
 - perioperative medical nutrition therapy, 386
 - postgastrectomy complications, 387–388
 - postgastrectomy syndromes, 390–393*b*
 - postvagotomy diarrhea, 392–393*b*
 - prevalence, 382
 - prognosis and survival, 382
 - risk factors, 382, 384*b*
 - Roux stasis syndrome, 390–391*b*
 - sample PES statements, 395
 - sarcopenia, 386
 - small gastric remnant, 390*b*
 - surgery, 384, 385*f*, 386
 - survivorship, 389
 - symptoms, 384
 - treatment of, 384, 386
 - types of, 382
- gastric outlet obstruction, medical nutrition therapy, 453
- Gastric Outlet Obstruction Grading Score, 388
- gastric stasis, postgastrectomy, 390–391*b*
- gastroesophageal reflux disease (GERD), enteral nutrition therapy, 228*b*
- gastrointestinal cancers, 405
 - anal carcinoma, 425–426
 - cholangiocarcinoma, 415, 417*f*, 418
 - colorectal cancer, 420–421, 422–423*f*, 424–425
 - enteral nutrition therapy, 228–229*b*
 - gallbladder carcinoma, 418
 - hepatocellular carcinoma, 414–415
 - interventions for treatment-related nutrition, 412–413*b*
 - neuroendocrine tumors of small bowel, 418–420
 - risk factors for types, 408–411*t*
 - sample PES statements, 427
 - treatment, 405, 412
 - types, 405, 406*f*, 407*t*
 - United States statistics, 407*t*
- GEDSA. *See* Global Enteral Device Supplier Association
- gefitinib (Iressa), protein-targeted agent, 174*b*
- gemcitabine (Gemzar), chemotherapy agent, 165*b*
- genetically engineered foods, 25
- genetically modified organisms, 25
- German Association for Nutritional Medicine, 555*b*
- germ cell tumors
 - category and nutrition, 256*b*
 - distribution of childhood cancer, 251*f*
- Gerson, Max, 604
- Gerson Institute, 604, 605
- Gerson Research Organization, 605
- Gerson Therapy, 604–605
- GetFit for Fight, 136–137*t*
- ginger (*Zingiber officinale*), 632
- Ginkgo biloba*, 117, 634
- Ginkgo Evaluation of Memory study, 634
- Global Enteral Device Supplier Association, 232–233
- glucose intolerance, hematologic malignancies, 293
- glutamine, 636
- glutathione S-transferase, 17
- GMOs. *See* genetically modified organisms
- Goldstein, Joseph L., 603
- Gonzalez regimen, 606
- goserelin (Zoladex), hormonal agents, 178–179*b*
- grading system, tumor, 4*b*
- graft-versus-host disease (GVHD), 306, 315–316
 - chronic, 321
 - dietary progression for gastrointestinal symptoms, 319–320*b*
 - hematopoietic cell transplantation, 315–316
 - survivorship, 321
 - therapies for prevention and treatment, 317–318*b*
- green tea (*Camellia sinensis*), 638
- gut bacteria, anti-inflammatory foods, 25–26
- GVHD. *See* graft-versus-host disease (GVHD)
- gynecologic cancers
 - cervical cancer, 500, 501*t*, 502
 - diagnosis, 502
 - endometrial and uterine cancer, 500, 501*t*
 - interventions for nutrition problems, 505–508
 - malignant bowel obstruction, 506–508
 - nutrition assessment, 504–505
 - ovarian cancer, 500, 501*t*
 - palliative care, 507–508
 - postoperative nutrition care, 506
 - sample PES statements, 509
 - sites and types, 503*f*
 - stents and percutaneous endoscopic gastrostomy tubes, 507
 - surgery, 507
 - survivorship, 508

- treatment, 502, 504
types, 499, 500, 502
United States statistics, 499t
- ## H
- Harris-Benedict equation, 83
hatha yoga, 97
HCT. *See* hematopoietic cell transplantation (HCT)
head and neck, normal anatomy, 475f
head and neck cancers
 calculating energy needs, 479
 comprehensive care, 477b, 478b
 counseling for patients with, 481b
 diagnosis, 474
 dysphagia, 480
 enteral nutrition, 482
 human papillomavirus, 473
 intervention for problems, 479–480, 482
 mucositis and thrush, 480
 nutrition assessment, 478–479
 nutrition impact symptoms, 476, 476b
 oral nutrition interventions, 480, 481b
 parenteral nutrition, 482
 radiation oncology team, 477b
 radiotherapy, 477
 risk factors, 473b
 sample PES statements, 483
 statistics for oral cavity and pharynx, 473b
 surgery, 478
 survivorship, 482b, 482–483
 symptoms, 474b
 systemic therapies, 478
 taste changes, 480
 treatment, 474, 476, 476b, 477–478
 types, 473–474
Healthy Eating Index, 590
Healthy Mediterranean-Style Diet, 2020–2025 Dietary Guidelines for Americans, 9th Edition, 586–587
Healthy Mediterranean-Style Eating Pattern, 114
Healthy US-Style Eating Pattern, 114
Healthy Vegetarian Diet, 2020–2025 Dietary Guidelines for Americans, 9th Edition, 588–589
Healthy Vegetarian Eating Pattern, 114
hematologic malignancies
 amyloidosis, 282, 290–291
 body composition and body mass index, 291–292
 bone health, 287–288
 cardiovascular events, 292
 chemotherapy-induced nausea and vomiting, 287
 classification, 283
 diagnosis of, 282–283
 glucose intolerance, 293
 Hodgkin lymphoma, 280
 hyperglycemia, 291
 hypertriglyceridemia, 291
 leukemia, 280
 lymphoma, 280
 malnutrition screening, 286
 multiple myeloma, 282
 non-Hodgkin lymphoma, 280
 nutrition assessment in patients, 285–287
 nutrition status before hematopoietic cell transplantation, 287
 osteoporosis, 292–293
 plasma cell neoplasms, 280, 282
 plasmacytomas, 282
 renal disease, 290
 risk factors, 279–280
 role of body mass index and weight, 279–280
 sample PES statements, 294
 serum vitamin D status, 288–290
 staging, 283
 survivorship and, 292–293
 treatment, 283–285
 types, 281f
hematopoietic cell transplantation (HCT), 234, 305
 acute graft-versus-host disease, 315–316, 317–318b
 baseline nutrition assessment before, 309–310b
 conditioning regimens, 306, 307f
 enteral nutrition, 316, 318, 319
 hyperglycemia, 314
 immunocompromised state, 308, 312, 313b
 impact of body weight on outcomes, 312–313
 infection, 315
 iron overload, 323
 monitoring nutrition support, 319, 321
 mucositis, 314
 neutrophil engraftment, 308t
 nutrient and fluid requirements, 308, 310–312b
 nutrition assessment, 306, 308
 nutrition status before, 287
 oral and gastrointestinal complications, 313–314
 parenteral nutrition, 318–319
 renal development, 314–315
 sample PES statements, 324
 sinusoidal obstructive syndrome, 314
 treatment for hematologic malignancies, 283–285
 treatment modalities, 323
 types, 305–306
hepatic fat accumulation, parenteral nutrition, 244b
hepatoblastoma, nutrition side effects, 258
hepatocellular carcinoma, 405. *See also* gastrointestinal cancers characteristics, 406f interventions for nutrition problems, 416–417b liver-directed therapies, 414 liver transplantation, 414 risk factors, 408–409t surgical resection, 414 systemic therapies, 414–415 treatment, 414–415 United States statistics, 407t
histamine H2-receptor antagonists and proton pump inhibitor (PPIs), enteral nutrition, 232b
HNCS. *See* head and neck cancers

- Hodgkin lymphoma, 279
 distribution of childhood
 cancer, 251*f*
 hematologic malignancies, 280
 nutrition impact symptoms,
 253, 256
 survival percentage in children,
 252*f*
 treatment, 285
- Holliday-Segar method
 equations for fluid needs, 267,
 267*b*
 hydration, 78
- home setting
 enteral nutrition, 233
 parenteral nutrition, 240
- hormone therapy, 158*f*
 breast cancer, 349
 cancer treatment, 177, 178–
 179*b*
- hospice. *See also* palliative care
 goals, 549
 initial nutrition assessment,
 550–552*f*
 nutrition screening and
 assessment, 548–552
 philosophies of, 545–546
 resources for, 557*b*
- Hospice Foundation of America,
 545
- HPA. *See* hypothalamic-pituitary-
 adrenal axis
- human papillomavirus, 177, 473
- Hydrastis canadensis* (goldenseal),
 117
- hydration, fluid requirements, 78,
 79*t*
- hydroxyurea (Hydrea),
 chemotherapy agent, 166*b*
- hyperglycemia
 brain tumors, 333–334
 enteral nutrition therapy, 226*b*
 hematologic malignancies, 291
 hematopoietic cell
 transplantation, 314
 pancreatic cancer, 452–453
 parenteral nutrition, 242*b*
- Hypericum perforatum* (St. John's
 wort), 117, 656
- hyperkalemia, enteral nutrition
 therapy, 227*b*
- hypernatremia, enteral nutrition
 therapy, 226*b*
- hyperphosphatemia, enteral
 nutrition therapy, 227*b*
- hyperthermic intraperitoneal
 chemotherapy, 258, 421
- hypertriglyceridemia
 hematologic malignancies, 291
 parenteral nutrition, 243*b*
- hyperventilation, 79*t*, 81
- hyponatremia, enteral nutrition
 therapy, 226*b*
- hypophosphatemia, enteral
 nutrition therapy, 227*b*
- hypothalamic-pituitary-adrenal
 axis, 92, 100
- ## I
- ibrutinomab tiuxetan (Zevalin),
 172*b*
- IBW. *See* ideal body weight
- IC. *See* indirect calorimetry
- idarubicin (Idamycin),
 chemotherapy agent, 168*b*
- ideal body weight, 83, 85
- ifosfamide (Ifex), chemotherapy
 agent, 163*b*
- IGF-1. *See* insulin-like growth
 factor 1
- IGRT. *See* image-guided radiation
 therapy
- IM. *See* integrative medicine
- image-guided radiation therapy, 184
- imatinib (Gleevec), protein-
 targeted agent, 174*b*
- immunosuppressed patients
 dietary guidelines following
 hematopoietic cell
 transplantation, 308, 312,
 313*b*
 parenteral nutrition, 242*b*
- immunotherapy, 158*f*
 agents used for, 171, 176
 cancer treatment, 171, 176–177
 cancer vaccines, 177
 chimeric antigen receptor
 T-cell therapy, 177
 lung cancer, 490
 modes of action, 171, 176
 nonspecific, 176, 176*b*
 oncolytic viral therapy, 176–
 177
- IMRT. *See* intensity-modulated
 radiation therapy
- Index for Nutritional Quality, 331
- indirect calorimetry, assessing
 energy needs, 80–81
- indole-3-carbinol (I3C), 626
- indolent lymphoma, treatment, 285
- induction chemotherapy
 acute lymphoblastic leukemia,
 284
 chronic myeloid leukemia, 284
- infection, hematopoietic cell
 transplantation, 315
- inflammation, anti-inflammatory
 foods and, 25–26
- Information for Healthcare
 Professionals, cannabis use, 572*b*
- Institute of Medicine, 76, 268, 288
- insulin-like growth factor 1 (IGF-1),
 13
 obesity and cancer, 43–44
- insulin sensitivity, prostate cancer,
 521*b*
- integrative medicine, 89
- intensity-modulated radiation
 therapy, 184
- interferon- α 2*b* (Intron A),
 nonspecific immunotherapy, 176*b*
- interleukin-2 (Aldesleukin),
 nonspecific immunotherapy, 176*b*
- Intermittent Fasting, 592–593
- International Agency for Research
 on Cancer, 37, 38*f*, 280
- International Association for
 Cannabinoid Medicines, 572*b*
- International Association of Yoga
 Therapists, 99*b*
- International Ketogenic Diet Study
 Group, 594
- International Organization for
 Standardization (ISO), 232
- International Prognostic Index, 288
- intestinal transit-inhibiting
 medications, 457*t*
- intraoperative radiation therapy,
 184–185
- iodine intake, thyroid cancer,
 531–532
- IORT. *See* intraoperative radiation
 therapy

Iowa Women's Health Study, 39, 113
ipilimumab (Yervoy), monoclonal antibodies, 170, 173*b*
iron, pancreatic cancer survivors, 461*b*
iron deficiency, after gastrectomy, 394*b*
iron overload, hematopoietic cell transplantation, 323
isoflavones, soy foods, 26, 27
Iyengar, yoga lineage, 97, 98*b*
Iyengar, B. K. S., 98*b*

J

Journal of Developments in Sustainable Agriculture, 115*b*
Journal of Parenteral and Enteral Nutrition, 62
Journal of the Academy of Nutrition and Dietetics, 62

K

Kabat-Zinn, Jon, 90*b*
Kelly, William Donald, 606
ketogenic diet, 594–595, *See also*
brain tumor
brain tumor, 335–337
implementing, 336–337, 337*b*
managing potential side effects of, 338–339*b*
resources for professionals, 338*b*
screening and monitoring, 335*b*
types of, 336
kidney cancer, nutrition-related side effects and interventions, 130*b*
Kripalu, yoga lineage, 98*b*, 100
Krishnamacharya, T., 98*b*
Kundalini, yoga lineage, 98*b*
Kushi Institute, 611

L

lactation
breastfeeding and, 23

practice points for, 23*b*
lactose intolerance, surgeries for
pancreatic cancer, 441*b*
large cell carcinoma, lung cancer, 487, 488*f*
Lasater, Judith, 98*b*
laxatives, enteral nutrition, 231*b*
lenalidomide (Revlimide),
angiogenesis inhibitors, 175*b*
leptin, obesity and cancer, 44
letrozole (Femara), hormonal agents, 178–179*b*
leukemia, 279
distribution of childhood cancer, 251*f*
hematologic malignancies, 280, 281*f*
nutrition-related side effects and interventions, 131*b*
leuprolide acetate (Lupron), hormonal agents, 178–179*b*
levonantradol, cannabinoids, 564–565
Life After Cancer Epidemiology Study, 117, 357
Lifestyle, Exercise, and Nutrition (LEAN), 138–139*t*
Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES), 144–145*t*
lifestyle interventions
breast cancer, 354, 361*b*
cancer survivors, 134*f*
lignans, breast cancer, 356
Linum usitatissimum (flaxseed), 628. *See also* flaxseed
Linus Pauling Institute, 115*b*
dietary supplements, 120*b*
functional foods, 115*b*
lipids
metabolism 75*b*
parenteral nutrition, 235–236, 237*b*
prostate cancer, 521*b*
LISA Trial, 140–141*t*
LiverTox, 116
Livingston-Wheeler therapy, 608–609
low anterior resection syndrome, colorectal cancer, 424–425
low-iodine diet
guidelines for, 534–535, 538

inconsistencies in guidelines, 535*b*
radioactive iodine, 534
side effects related to, 539
thyroid cancer, 534–535, 536–538*b*, 538
Lugano Classification System, 283
lung and bronchus cancer, side effects and interventions, 128*b*
lung cancer
adenocarcinoma, 487, 488*f*
chemotherapy, 489–490
diagnosis, 489
identifying patients at high nutritional risk, 493*b*
immunotherapy, 490
incidence, 487
interventions for nutrition problems, 491–493
large cell carcinoma, 487, 488*f*
malnutrition and weight loss, 492
nutrition assessment, 490–491
radiotherapy, 490
risk factors, 487
sample PES statements, 494
sarcopenia and muscle loss, 492–493
sarcopenic obesity, 493
small cell carcinoma, 487, 488*f*
squamous cell carcinoma, 487, 488*f*
surgery, 489
survivorship, 494
targeted therapies, 489–490
treatment, 489–490
types, 487, 488*f*
luteinizing hormone-releasing hormone (LHRH) agonists, hormonal agents, 178–179*b*
lycopene-rich fruits and vegetables, prostate cancer, 523*b*
lymphedema, breast cancer, 350–351
lymphoma, hematologic malignancy, 279, 280, 281*f*

M

macrobiotic diet, 610–611
macronutrient metabolism, systemic inflammation, 75*b*

- macronutrient needs
 carbohydrates, 77–78, 78*t*
 Dietary Reference Intakes (DRIs), 77–78, 78*t*
 fats, 77–78, 78*t*
 lung cancer, 491
 protein, 77, 77*t*, 78*t*
- Madaus GmbH, 654
- magnetic resonance imaging (MRI), 40, 282, 375, 489
- malabsorption
 considerations, 208*b*
 definition, 208*b*
 interventions, 209*b*
 medical nutrition therapy, 448, 451–452
 pancreatic cancer, 446, 451–452
 pharmacotherapy, 209*b*
 postoperative oral diet, 455
 severity grades, 208*b*
- malignant bowel obstruction
 gynecologic cancers, 506–508
 palliative care, 507–508
 stents and percutaneous endoscopic gastrostomy tubes, 507
 surgery, 507
- malnutrition. *See also* nutrition
 cancer patients and, 59
 childhood cancer, 259
 clinical characteristics in oncology patient, 67
 clinical characteristics supporting diagnosis of, 68–69*t*
 definition, 59
 esophageal cancer, 379
 gastric cancer, 388
 gynecologic cancers, 505
 lung cancer, 492
 nutrition care process and, 62
 pediatric consensus criteria, 260*t*
 risk factors in pediatric cancer patients, 259*b*
 screening for, 59–61
 screening hematologic malignancies, 286
- Malnutrition Screening Tool, 286
- Malnutrition Universal Screening Tool, 548
- Marihuana Tax Act (1937), 563, 573
- mastectomy, breast cancer, 349
- MBCR. *See* mindfulness-based cancer recovery
- MBIs. *See* mind-body interventions
- measured resting energy expenditure, 76
- mechlorethamine (nitrogen mustard), chemotherapy agent, 164*b*
- Medicaid, 545
- medical nutrition therapy (MNT), 127. *See also* cancer survivors
 ascites, 453–454
 assessing nutritional inadequacies, 132–135
 conditioning regimens, 306
 delayed gastric emptying, 456
 diabetes mellitus, 452–453
 diarrhea and rapid intestinal transit, 456–457
 dumping syndrome, 381*b*
 gastric cancer, 386
 gastric outlet obstruction, 453
 hyperglycemia, 452–453
 malabsorption and pancreatic exocrine insufficiency, 448, 451–452
 nutrition impact symptoms, 195–196
 palliative care, 546
 perioperative, for pancreatic cancer, 454–455
 postoperative pancreatic fistula, 457
 posttreatment weight management, 133, 135
 prostate cancer, 520, 521*b*
 small bowel obstruction, 453
- medical oncology, 157, 158*f*
- Medicare, 233, 545
- Medicare Coverage Database, 233
- meditation, 89
 mind-body intervention, 90*b*, 96–97
 resources, 102*b*
- medullary thyroid carcinoma, 533*f*
- medulloblastoma, category and nutrition, 255*b*
- MedWatch program, FDA, 116
- megestrol acetate (Megace)
 hormonal agents, 178–179*b*
 pediatric oncology, 269*b*
- melanoma, distribution of
 childhood cancer, 251*f*
- melatonin, 640
- melfhalan (Alkeran), chemotherapy agent, 164*b*
- Memorial Sloan Kettering Cancer Center, dietary supplements, 120*b*
- men, cancer types common in US, 1*t*
- mercaptopurine (6-MP), chemotherapy agent, 166*b*
- metabolic bone disease, parenteral nutrition, 245*b*
- metabolic syndrome, hematopoietic cell transplantation, 321
- metastatic bone pain, possible side effects of radiopharmaceuticals, 192*b*
- methotrexate (MTX), chemotherapy agent, 5, 166*b*
- MGUS. *See* monoclonal gammopathy of undetermined significance
- microbiome, anti-inflammatory foods and, 25–26
- Micronutrient Information Center
 dietary supplements, 120*b*
 functional foods, 115*b*
- micronutrients
 Dietary Reference Intake (DRI), 79
 functional foods, 113
 lung cancer, 491
 medical conditions and cancer treatments affecting, 79, 80*b*
 needs, 79
 pancreatic cancer survivors, 458, 459*b*, 460–461*b*
 pediatric cancer patients, 267–268, 268*t*
- Mifflin–St. Jeor equation, 82*f*, 83, 84
- milk thistle (*Silybum marianum*), 117
- Miller, Richard, 99*b*
- mind-body interventions, 89
 acupuncture, 94–95
 mechanisms of action for stress and, 92, 94
 meditation, 96–97
 practical applications of, 100–101

qigong, 96
 resources, 102*b*
 selected popular, 90*b*
 tai chi, 96
 yoga, 97, 99–100
 mindfulness-based cancer recovery, 97
 mindfulness-based stress reduction (MBSR), mind-body intervention, 90*b*, 96–97
 mineral intake. *See also* vitamin(s)
 colorectal cancer, 425
 parenteral nutrition, 244*b*
 patients with hepatic compromise, 416*b*
 Mini Nutritional Assessment, 548
 mitomycin-C (Mutamycin), chemotherapy agent, 167*b*
 MNT. *See* medical nutrition therapy (MNT)
 Modified-Atkins, 136–137*t*
 modified radical mastectomy, breast cancer, 349
 monoclonal antibodies, targeted therapy, 170–171, 172–173*b*
 monoclonal gammopathy of undetermined significance, hematologic malignancies, 281*f*, 282
 mREE. *See* measured resting energy expenditure
 MRI. *See* magnetic resonance imaging (MRI)
 mucositis
 chemotherapy-induced, and breast cancer, 352–353
 head and neck cancers, 480
 hematopoietic cell transplantation, 314
 Multiethnic Cohort Study, 118
 multiple myeloma, 279, 281*f*
 diagnosis of, 282
 treatment, 284
 multivitamin and mineral (MVM) supplement, 117–118

N

nabilone, cannabinoids, 564–565
 nabiximols, cannabinoids, 565
 N-acetylcysteine (NAC), 642

National Academies of Science, Engineering, and Medicine, 76, 268, 288
 National Cancer Institute, 1, 252, 253*b*, 412, 605
 cancer survivorship, 148*b*
 Common Terminology Criteria for Adverse Events (CTCAE), 195, 196*b*
 lung cancer, 487
 National Coalition for Cancer Survivorship, cancer survivorship, 149*b*
 National Comprehensive Cancer Network, 135, 157, 333, 405
 breast cancer treatments, 349
 Clinical Practice Guidelines in Oncology for Uterine Cancer, Ovarian Cancer and Cervical Cancer, 502
 esophageal cancer, 375
 head and neck cancers, 474, 477*b*, 482
 lung cancer, 489
 multiple myeloma, 284
 pancreatic cancer, 437
 physical activity guidelines and cancer, 43*b*
 practice points for cancer survivors, 24*b*
 prostate cancer, 517, 518*b*
 website, 283
 National Conference of State Legislatures, State Medical Marijuana Laws, 572*b*
 National Health and Nutrition Examination Survey (NHANES), 360, 611
 National Health Interview Survey, 89, 91, 92
 National Institute of Diabetes and Digestive and Kidney Diseases, 116, 290
 National Institutes of Health, 116, 606
 National Center for Complementary and Integrative Health, 89
 Office of Dietary Supplements, 120*b*
 National Kidney Foundation, 290, 292

National Library of Medicine, 116
 National Lipid Association, 522
 National Osteoporosis Foundation, 288
 nausea and vomiting
 chemotherapy-induced, 287
 chemotherapy-induced, and breast cancer, 352
 considerations, 210*b*
 definition, 210*b*
 enteral nutrition therapy, 228*b*
 interventions, 211*b*
 pharmacotherapy, 211*b*
 prevalence in cancer patients, 547*t*
 severity grades, 210*b*
 NCCN. *See* National Comprehensive Cancer Network
 NCI. *See* National Cancer Institute
 NCI-Designated Cancer Centers, 91, 94–95
 neck cancers. *See* head and neck cancers
 neorectal reservoirs, colorectal cancer, 425
 NETSBs. *See* neuroendocrine tumors of small bowel
 neuroblastoma
 distribution of childhood cancer, 251*f*
 nutrition side effects, 257
 survival percentage in children, 252*f*
 neuroendocrine tumors of small bowel, 405. *See also* gastrointestinal cancers
 carcinoid syndrome, 419–420
 characteristics, 406*f*
 diagnostic testing, 418–419
 interventions for nutrition problems, 412–413*b*, 419–420
 niacin deficiency, 420
 radiopharmaceuticals, 419
 risk factors, 410–411*t*
 secretory diarrhea, 420
 somatostatin analogue therapy, 419
 surgery, 419
 treatment, 419
 United States statistics, 407*t*
 neuropathy, breast cancer, 352

- niacin deficiency, neuroendocrine tumors of small bowel, 420
- NIH. *See* National Institutes of Health
- NIS. *See* nutrition impact symptoms (NIS)
- nivolumab (Opdivo), monoclonal antibodies, 170, 173*b*
- non-Hodgkin lymphoma, 279
 - distribution of childhood cancer, 251*f*
 - hematologic malignancies, 280
 - nutrition impact symptoms, 256–257
 - nutrition-related side effects and interventions, 129*b*
 - survival percentage in children, 252*f*
 - treatment, 284–285
- Norwegian County Study, 113
- Nurses' Health Study, 39, 360
- Nurses' Health Study II, 358
- nutrients
 - anti-inflammatory foods, 25
 - gynecologic cancers, 505
 - lung cancer, 490–491
 - possible effects on carcinogenesis stages, 5*f*
 - requirements during hematopoietic cell transplantation, 308, 311–312*b*
- nutrition. *See also* cancer prevention; enteral nutrition; functional foods; malnutrition; parenteral nutrition
 - cancer prevention, 8*b*
 - cancer treatment, 8*b*
 - carcinogenesis and, 4, 5
 - esophageal cancer and postoperative, 379–380
 - evidence-based assessment, 61–62
 - flaxseed, 27–28
 - foods promoting weight gain, 19, 19*b*
 - gastric cancer, 387, 387*b*
 - hospice initial assessment, 550–552*f*
 - long-term cancer survivorship, 9*b*
 - oncology-related assessment, 62–67*b*
 - posttreatment, 7, 9*b*
 - refeeding syndrome, 85
 - role in cancer treatment, 6–7
 - screening tools, 60–61
- Nutritional Risk Screening, 504
- nutrition assessment
 - brain tumors, 333
 - breast cancer, 349–350
 - gynecologic cancers, 504–505
 - hematopoietic cell transplantation, 309–310*b*
 - for identifying inadequacies, 132–135
 - patients with hematologic malignancies, 285–287
- nutrition assessment in childhood cancer
 - calcium, 267, 268*t*
 - children with amputations, 262, 262*t*
 - energy requirements, 262, 265*t*, 266
 - estimating nutrition requirements, 262, 266–268
 - fluid requirements, 267, 267*b*
 - micronutrients, 267–268, 268*t*
 - protein requirements, 266–267, 267*t*
 - vitamin D, 267–268, 268*t*
- Nutrition Care Process, 75
- Academy of Nutrition and Dietetics, 62–67*b*
- functional foods in cancer, 114
- nutrition impact symptoms (NIS)
 - acute lymphoblastic leukemia, 253
 - acute myeloid leukemia, 253
 - anorexia and early satiety, 196, 196–197*b*
 - chimeric antigen receptor (CAR) T-cell therapy, 258
 - chronic graft-versus-host disease, 322*b*
 - constipation, 196, 200–201*b*
 - diarrhea, 196, 202–203*b*
 - dysphagia, 196, 204–205*b*
 - esophageal cancer, 376*b*, 377
 - Ewing sarcoma, 258
 - fatigue, 196, 206–207*b*
 - gastric cancer, 386
 - head and neck cancers, 476*b*
 - hepatoblastoma, 258
 - Hodgkin lymphoma, 253, 256
 - hyperthermic intraperitoneal chemotherapy (HIPEC), 258
 - malabsorption, 196, 208–209*b*
 - medical nutrition therapy for, 195–196
 - nausea and vomiting, 196, 210–211*b*
 - neuroblastoma, 257
 - oral candidiasis, 196, 214*b*
 - oral mucositis and esophagitis, 196, 212–213*b*
 - osteosarcoma, 258
 - pancreatic tumors, 441*b*
 - prevalence in cancer patients, 547*t*
 - primary brain tumors medications, 334*b*
 - quality of life and, 546–548
 - rhabdomyosarcoma, 257
 - surgeries for pancreatic cancer, 441*b*
 - taste and smell changes, 196, 198–199*b*
 - thyroid cancer, 539
 - tools for assessing, 195
 - Wilms tumor, 257
 - xerostomia, 196, 215*b*
- Nutrition Risk Screening, 504, 548
- Nutrition Screening Tool for Childhood Cancer (SCAN), 260–261, 261*f*
- ## O
- oat by-products, functional foods, 113
- obesity, 51
 - anthropometric measures, 40, 63*b*
 - cachexia and, 44–46
 - cancer risk and, 37, 39
 - cancer treatment and, 70
 - direct measures, 40–43
 - mechanisms of energetics and cancer, 43–44
 - sarcopenia and, 45–46
- Obesity Society, The, 47
- Office of Dietary Supplements, National Institutes of Health, 120*b*

- Oley Foundation, 233
- omega-3 fatty acids, 644
- breast cancer, 358
 - breast cancer and supplements, 363–364
 - flaxseed and, 27
 - foods supplying, 26
 - lung cancer, 491
 - prostate cancer, 524*b*
 - seafood content, 359*t*
- Oncology Nursing Society, 149*b*, 196
- Oncology Nutrition Evidence Analysis Work Group, 60, 67
- oncology population
- clinical characteristics of malnutrition, 67
 - enteral nutrition for, 219–220
 - parenteral nutrition, 235*b*
 - weight management in, 70
- oncology-related nutrition
- assessment, 62–67*b*
 - anthropometric measurements, 63*b*
 - biochemical data, medical tests and procedures, 64*b*
 - client history, 67*b*
 - food and nutrition history, 62–63*b*
 - nutrition-focused physical findings, 65–66*b*
- oral and gastrointestinal
- complications, hematopoietic cell transplantation, 313–314
- oral candidiasis
- considerations, 214*b*
 - definition, 214*b*
 - interventions, 214*b*
 - pharmacotherapy, 214*b*
 - severity grades, 214*b*
- oral cavity, normal anatomy, 475*f*
- oral cavity cancer
- nutrition-related side effects and interventions, 130*b*
 - United States statistics, 473*b*
- oral mucositis
- considerations, 212–213*b*
 - definition, 212*b*
 - interventions, 213*b*
 - pharmacotherapy, 213*b*
 - severity grades, 212*b*
- Oregon State University
- dietary supplements, 120*b*
 - functional foods, 115*b*
- organic foods. *See also* dietary supplements/functional foods; functional foods
- health-related interest in, 24–25
 - pesticide residue, 24
- osteoporosis, hematologic malignancies, 292–293
- osteosarcoma, nutrition side effects, 258
- ostomy management, colorectal cancer, 424
- ovarian cancer, 499, 500. *See also* gynecologic cancers
- calcium and, 500
 - diagnosis, 502
 - nutrition-related side effects and interventions, 131*b*
 - risk and protective factors, 501*b*
 - site and type, 503*f*
 - treatment, 502, 504
 - United States statistics, 499*t*
- Overhydration, enteral nutrition therapy, 226*b*
- oxaliplatin (Eloxatin), chemotherapy agent, 164*b*

P

- paclitaxel (Taxol), chemotherapy agent, 169*b*
- paclitaxel protein bound (Abraxane), chemotherapy agent, 169*b*
- pain medications, enteral nutrition, 231*b*
- PAL. *See* physical activity levels
- palliative care. *See also* hospice
- artificial hydration, 553, 556
 - artificial nutrition, 553, 554–555*b*
 - decision for use of artificial nutrition or hydration, 556–557
 - definition, 545
 - gastric cancer, 388–389
 - goals, 549
 - gynecologic cancers, 507–508
 - hospice initial nutrition assessment, 550–552*f*
 - nutritional screening and assessment, 548–552
 - nutrition impact symptoms, 546–548
 - parenteral nutrition, 245
 - philosophies of, 545–546
 - resources for, 557*b*
- Panax ginseng, 117
- pancreas, 435
- normal anatomy of, 435*f*
- pancreatic adenocarcinoma, 436*b*
- risk factors for, 437
 - treatment agents, 438, 438*b*
- pancreatic cancer
- ascites, 453–454
 - bone density, 458–459
 - chemotherapy, 438*b*
 - chyle leak, 458
 - common symptoms, 447*b*
 - deficiency replacement, 458, 460–461*b*
 - diabetes mellitus, 452–453
 - diagnosis, 437
 - diet modification, 452
 - distal pancreatectomy, 441*b*, 445*f*
 - drug combinations, 438
 - enteral nutrition, 451
 - gastric outlet obstruction, 453
 - gastrointestinal transit time changes, 455–457
 - hyperglycemia, 452–453
 - immunotherapy, 438*b*
 - interventions for nutrition problems, 446, 451–454
 - malabsorption and pancreatic exocrine insufficiency, 446, 451–452
 - nutrition assessment, 440, 446
 - nutrition impact symptoms, 441*b*
 - nutrition-related side effects and interventions, 131*b*
 - pancreatic enzyme replacement dosing regimens, 449*t*
 - pancreatic enzyme replacement optimization, 448, 450*f*
 - pancreatic enzyme replacement products, 448, 449*t*
 - pancreatic enzymes, 448, 451
 - pancreaticoduodenectomy, 441*b*, 442*f*, 443*f*

- perioperative nutrition, 454–458
- postoperative pancreatic fistula, 457
- pylorus-preserving
 - pancreaticoduodenectomy, 441*b*, 444*f*
- radiotherapy, 439
- sample PES statements, 462
- small bowel obstruction, 453
- surgery, 440, 441*b*, 442*f*, 443*f*, 444*f*, 445*f*
- survivorship, 458–459, 459*b*, 460–461*b*
- systemic therapy, 437–438
- targeted therapy, 438*b*
- treatment, 437, 439–440
- types, 436–437
- United States statistics, 436*b*
- pancreatic enzymes
 - managing malabsorption, 448
 - over-the-counter (OTC)
 - preparation, 448, 451
 - replacement optimization, 450*f*
 - replacement products, 448, 449*t*
 - replacement therapy, 448, 451
 - resources for financial assistance for products, 451*b*
- pancreatic exocrine insufficiency, 381
 - diet modification, 452
 - enteral nutrition, 451
 - malabsorption and, 446, 451–452
 - medical nutrition therapy, 448, 451–452
 - postoperative oral diet, 455
 - signs and symptoms, 448*b*
 - surgeries for pancreatic cancer, 441*b*
- pancreatic neuroendocrine tumor, 436*b*
- pancreaticoduodenectomy, 440
 - anatomical reconstruction, 443*f*
 - chyle leak, 458
 - nutrition impact symptoms, 441*b*
 - resected anatomy, 442*f*
- panitumumab (Vectibix), monoclonal antibodies, 173*b*
- papillary thyroid carcinoma, 533*f*
- parasympathetic nervous system, 92, 93*f*
- parenteral nutrition, 219. *See also* enteral nutrition
 - access, 234–235
 - amino acids, 235–236, 237*t*
 - complications of, 240, 242–245*b*
 - components of, 235–236, 238–240
 - dextrose, 235–236, 237*t*
 - electrolyte requirements for adults, 236, 238, 238*t*
 - esophageal cancer, 379
 - gastric cancer, 387, 387*b*
 - gastrointestinal cancers, 412*b*, 413*b*
 - guidelines for patients with advanced cancer, 554–555*b*
 - gynecologic cancers, 508
 - head and neck cancers, 482
 - hematopoietic cell transplantation, 318–319
 - in home setting, 240, 245
 - indications for, 234, 235*b*
 - initiation of, 240
 - lipids, 235–236, 237*t*
 - macronutrients in, 235–236, 237*t*
 - monitoring of, 240, 241*b*
 - palliative care and end of life, 245
 - patients with advanced cancer, 553
 - trace element additives, 238*t*, 238–240
 - vitamins, 238–240, 239*t*
- Pathways Study, 352
- patient-generated subjective global assessment, 286, 548
- Pattabhi Jois, Sri K., 98*b*
- pediatric oncology. *See also* childhood cancer
 - anthropometric measurements, 263*b*
 - appetite stimulants for, 269*b*
 - biochemical data, 263–264*b*
 - clinical and medical history, 264*b*
 - dietary and activity assessment, 264*b*
 - estimated energy requirement equations, 265*t*
- nutrition-focused physical findings, 264*b*
- nutrition interventions and support, 268–270
- recommended assessment parameters, 263–264*b*
- resting energy expenditure equations, 266*t*
- PEI. *See* pancreatic exocrine insufficiency
- pembrolizumab (Keytruda), monoclonal antibodies, 170, 173*b*
- pemetrexed (Alimta), chemotherapy agent, 166*b*
- Penn State equations, energy needs, 82*f*, 83, 84
- Pen Ts'ao Ching*, China, 563
- peptide receptor radionuclide therapy, 419
- personalized medicine, 161, 170
- pertuzumab (Perjeta), monoclonal antibodies, 172*b*
- PES (cancer-specific nutrition diagnosis) statements
 - breast cancer, 364
 - esophageal cancer, 395
 - gastric cancer, 395
 - gastrointestinal cancers, 427
 - gynecologic cancers, 509
 - head and neck cancers, 483
 - hematologic malignancies, 294
 - hematopoietic cell transplantation, 324
 - lung cancer, 494
 - pancreatic and bile duct cancers, 462
 - primary brain tumors, 342
 - prostate cancer, 525
 - thyroid cancer, 540
- pesticides
 - organic foods and, 24–25
 - residue, 24
 - washing produce, 25
- PET. *See* positron emission tomography (PET)
- pharmaceuticals, plants and, 117
- pharmacokinetics, cannabis, 568*t*, 568–569
- pharynx, normal anatomy, 475*f*
- pharynx cancer
 - nutrition-related side effects and interventions, 130*b*
 - United States statistics, 473*b*

- physical activity, 37, 51
 breast cancer, 360
 cancer prevention, 16–17
 cancer risk and, 40
 cancer survivorship and, 49–51
 guidelines for cancer
 prevention and survivorship,
 41–43*b*
 levels, 81*b*
 long-term survivorship, 50–51,
 147
 mechanisms of energetics and
 cancer, 44
 practice points, 17*b*
 prescriptions and referrals, 51
 prostate cancer, 520
- Physicians' Health Study II, 118
- phytochemicals
 anti-inflammatory foods, 25
 foods containing, 25
 predominantly plant-based diet,
 17–19
 resveratrol, 21*b*
- phytoestrogens
 safety, 116
 soy and, 26
- pineal gland, 332*f*
- pituitary gland, 332*f*
- plant-based diet. *See also* diets
 cancer and predominantly,
 17–19
 practice points, 18*b*
 prostate cancer, 517, 519
- plants, dietary supplements, 117
- plasma cell neoplasms, hematologic
 malignancy, 280, 281*f*, 282
- plasmacytomas, hematologic
 malignancies, 281*f*, 282
- Polyporus versicolor*, 660
- Pooling Project, breast cancer, 355
- positron emission tomography
 (PET), 282, 375, 489
- postgastrectomy
 complications, 387–388
 syndromes, 390–393*b*
- postoperative nutrition
 esophageal cancer, 379–381
 gynecologic cancers, 506
 pancreaticoduodenectomy, 455
- postoperative pancreatic fistula,
 medical nutrition therapy, 457
- postvagotomy diarrhea,
 postgastrectomy, 392–393*b*
- poultry, 20
 prostate cancer, 523*b*
- prebiotics, functional foods, 113
- precision medicine, 161, 170
- predicted resting energy
 expenditure, 76, 80
- predictive equations
 decision tree for, 82*f*
 energy needs, 81, 83–85
- pREE. *See* predicted resting energy
 expenditure
- primary brain tumor, 331. *See also*
 brain tumor
 nutrition impact symptoms for
 medications for, 334*b*
- processed meats. *See also* red meat
 cancer prevention, 19–20
 practice points, 20*b*
 recommendations, 14*b*
 term, 19
- Progenitor cryptocides*, 608
- progesterones, hormonal agents,
 178–179*b*
- prostate cancer, 515
 animal foods, 20
 body weight and physical
 activity, 520
 carcinoma of prostate gland,
 516*f*
 cases in United States, 515*b*
 dairy products, calcium and
 vitamin D, 519–520
 diagnosis, 515, 517
 dietary supplements, 520
 eggs and choline, 520
 fat consumption, 519
 interventions for nutrition
 problems, 520, 522
 medical nutrition therapy, 521*b*
 nutrition recommendations for
 survivors, 523–524*b*
 nutrition-related side effects
 and interventions, 128*b*
 plant-based diets, 517, 519
 prostate-specific antigen (PSA),
 515
 risk factors, 515, 517*b*
 sample PES statements, 525
 survivorship, 522, 523–524*b*
 treatment, 517, 518*b*
- protein
 Dietary Reference Intake
 (DRI), 77, 77*t*
- estimating needs for pediatric
 cancer patients, 262, 266–
 267, 267*t*
 lung cancer, 491
 metabolism, 75*b*
 patients with hepatic
 compromise, 416*b*
 requirements during
 hematopoietic cell
 transplantation, 311*b*
- Pulling Through Study, 353
- pylorus-preserving
 pancreaticoduodenectomy, 440.
See also pancreatic cancer
 anatomical reconstruction,
 444*f*
 nutrition impact symptoms,
 441*b*

Q

- qigong, 89
 mind-body intervention, 90*b*,
 96
 resources, 102*b*
- QOL. *See* quality of life
 quality of life, 89, 185
 nutrition impact symptoms and,
 546–548
 palliative care and hospice, 545
 pancreatic cancer, 440
 yoga, 100
- quercetin, 646

R

- race, cancer survival rates by, 2*f*
- radiation
 Hodgkin lymphoma, 285
 multiple myeloma, 284
 non-Hodgkin lymphoma,
 284–285
- radiation-induced diarrhea,
 gynecologic cancers, 505–506
- radiation oncology, 158*f*, 183
 brachytherapy, 183, 185, 188*b*,
 189*b*, 190*b*
 direct effects of, 183

external beam radiation therapy (EBRT), 183, 184–185
 radiopharmaceutical therapy, 183, 190–191, 192*b*

radiation therapy
 prostate cancer, 521*b*
 side effects of, 186*f*, 187*b*

radical mastectomy, breast cancer, 349

radioactive iodine therapy
 side effects related to, 539
 thyroid cancer, 534–535, 538

radiopharmaceutical therapy, 183
 neuroendocrine tumors of small bowel, 419
 possible side effects for metastatic bone pain, 192*b*
 radioactive substances, 191
 radioimmunotherapy agents, 190

radiotherapy
 antioxidant supplements and, 118–119
 head and neck cancers, 477, 477*b*
 lung cancer, 490
 ovarian cancer, 504
 pancreatic cancer, 439
 thyroid cancer, 534–535, 538

radium 223 (Xofigo), 191
 possible side effects for metastatic bone pain, 192*b*

raloxifene (Evista), hormonal agents, 178–179*b*

raw food plan, 612–613

RDA method, hydration, 78

RDNs. *See* registered dietitian nutritionists

Reach Out to Enhance Wellness (RENEW), 142–143*t*

Reach Out to Enhance Wellness in Older Survivors (RENEW), 144–145*t*

reactive oxygen species, 118

Recommended Dietary Allowance, 5, 76, 266, 268*t*, 289

red meat. *See also* processed meats
 breast cancer, 358
 cancer prevention, 19–20
 practice points, 20*b*
 recommendations, 14*b*
 term, 19

REE. *See* resting energy expenditure

refeeding syndrome, 85

registered dietitian nutritionist, 157, 222
 palliative care, 546
 registered dietitian nutritionists, 23, 47, 60, 70, 101, 114, 195

reishi mushroom (*Ganoderma lucidum*), 648

Remifemin, 620

renal disease
 hematologic malignancies, 290
 hematopoietic cell transplantation, 314–315

resistance starch, functional foods, 112–113

respiratory quotient, 81*b*

resting energy expenditure, 76, 80, 81*b*
 equations for critically ill children, 266*t*
 pediatric cancer, 262, 266*t*
 Weir formula for, 81

resting metabolic rate, 81*b*

Restorative yoga, 98*b*

resveratrol, 21*b*

resveratrol (trans-3,5,4'-trihydroxystilbene), 650

retinoblastoma, distribution of childhood cancer, 251*f*

rhabdomyosarcoma
 distribution of childhood cancer, 251*f*
 nutrition side effects, 257

rituximab (Rituxan), monoclonal antibodies, 172*b*

RMR. *See* resting metabolic rate

ROS. *See* reactive oxygen species

Roux stasis syndrome, postgastrectomy, 390–391*b*

RQ. *See* respiratory quotient

S

safety, dietary supplements, 116

St. John's wort (*Hypericum perforatum*), 656

samarium 153 (Quadramet), 191
 possible side effects for metastatic bone pain, 192*b*

sarcopenia
 esophageal cancer, 379
 gastric cancer, 386
 hematologic malignancies, 288
 lung cancer, 492–493
 obesity and, 45–46
 patients with hepatic compromise, 416*b*
 prostate cancer, 521*b*

SCAN. *See* Nutrition Screening Tool for Childhood Cancer (SCAN)

SCCM. *See* Society of Critical Care Medicine

screening
 cancer, 2–3
 malnutrition, 59–61
 tools for nutrition, 60–61

secretory diarrhea, neuroendocrine tumors of small bowel, 420

SELECT. *See* Selenium and Vitamin E Cancer Prevention Trial

selective estrogen receptor moderators, hormonal agents, 178–179*b*

selenium
 dietary supplement, 22, 79
 pancreatic cancer survivors, 461*b*
 trace mineral, 652

Selenium and Vitamin E Cancer Prevention Trial, dietary supplements, 22, 652

sentinel lymph node biopsy, breast cancer, 349

SGA. *See* subjective global assessment

short-chain fatty acids, functional foods, 113

Silybum marianum (milk thistle), 117, 654

single-point, 96

sinusoidal obstructive syndrome, hematopoietic cell transplantation, 314

SIO. *See* Society for Integrative Oncology

small bowel obstruction, medical nutrition therapy, 453

small cell carcinoma, lung cancer, 487, 488*f*

small gastric remnant, postgastrectomy, 390*b*

small-molecule drugs
 angiogenesis inhibitors, 171, 175*b*
 protein-targeted agents, 171, 174*b*
 targeted therapy, 171, 174–175*b*
 smell. *See* taste and smell changes
 SNS. *See* sympathetic nervous system
 Society for Integrative Oncology
 acupuncture, 95
 evidence grades, 94*b*
 meditation, 96
 qigong, 96
 yoga, 100
 Society of Critical Care Medicine, 84, 85, 225
 somatostatin analogue therapy, neuroendocrine tumors of small bowel, 419
 sorafenib (Nexavar), protein-targeted agent, 174*b*
 soy foods
 breast cancer, 356–357
 breast cancer survivors and, 26–27
 dietary soy amounts, 27
 human data on consumption, 26
 isoflavone content of, 357*t*
 nutrition, 26–27
 phytoestrogens, 26
 prostate cancer, 517, 519, 524*b*
 Spanish Society of Medical Oncology, 555*b*
 spinal cord, 332*f*
 squamous cell carcinoma, lung cancer, 487, 488*f*
 SRS. *See* stereotactic radiosurgery
 SRT. *See* stereotactic radiation therapy
 staging, cancer, 3–4
Staphylococcus aureus, 268, 604
 anti-methicillin-resistant, 564
 steatosis, parenteral nutrition, 244*b*
 Stepping Stone, 138–139*t*
 stereotactic radiation therapy, 184
 stereotactic radiosurgery, 184
 stomach, normal anatomy of, 383*f*.
See also gastric cancer
 stress, mind-body interventions and, 92, 94

strontium 89 (Metastron), 191
 possible side effects for
 metastatic bone pain, 192*b*
 subjective global assessment, 505
 categories, 333
 patient-generated, 286, 504–505, 548
 SUCCEED. *See* Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED) trial
 sugar-sweetened beverages
 cancer and, 20–21
 practice points, 21*b*
 recommendations, 14*b*
 sunitinib (Sutent), 171
 protein-targeted agent, 174*b*
 surgical oncology, 158*f*
 Surveillance, Epidemiology, and End Results Program, National Cancer Institute (NCI), 1
 Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED) trial, 133, 136–137*t*
 sympathetic nervous system, 92, 93*f*, 100
 systemic inflammation
 cancer and, 75
 macronutrient metabolism, 75*b*
 systemic therapy, breast cancer, 349

T

tai chi, 89
 mind-body intervention, 90*b*, 96
 resources, 102*b*
 talimogene laherparepvec (Imlygic) (T-VEC), oncolytic viral therapy, 176–177
 tamoxifen citrate (Novaldex), hormonal agents, 178–179*b*
 targeted therapy, 158*f*
 cancer treatment, 170–171
 lung cancer, 489–490
 monoclonal antibodies, 170–171, 172–173*b*
 side effects of, 170
 small-molecule drugs, 171, 174–175*b*

taste and smell changes
 considerations, 198*b*
 definition, 198*b*
 head and neck cancers, 480
 interventions, 199*b*
 pharmacotherapy, 198*b*
 severity grades, 198*b*
 taxanes, chemotherapy, 169*b*
 TBI. *See* total body irradiation
 TCM. *See* traditional Chinese medicine
 telephone counseling, cancer survivors, 138–141*t*
 temozolomide (Temodar), chemotherapy agent, 164*b*
 temsirolimus (Torisel), protein-targeted agent, 174*b*
 teniposide (Vumon, VM-26), chemotherapy agent, 168*b*
 terpenoids, cannabis, 565*b*
 tetrahydrocannabinol, cannabis, 563, 564–567
 tetrahydrocannabinolic acid, 563
 Text4Diet, 142–143*t*
 thalidomide (Thalomid),
 angiogenesis inhibitors, 175*b*
 THC. *See* tetrahydrocannabinol
 THCA. *See* tetrahydrocannabinolic acid
 theanine, 658
 Therapeutic Research Center, dietary supplements, 120*b*
 thiamine supplementation, 85
 thioguanine (6-TG), chemotherapy agent, 166*b*
 thiotepa (Thioplex), chemotherapy agent, 164*b*
 Thorne Research, 654
 three-dimensional conformal radiation therapy (3D-CRT), 184
 thrush, head and neck cancers, 480
 thyroid cancer
 anaplastic thyroid carcinoma, 533*f*
 chemotherapy, 532, 534
 cruciferous vegetable intake, 532
 dietary risk factors, 531–532
 distribution of childhood cancer, 251*f*
 dysphagia, 539
 follicular thyroid carcinoma, 533*f*

interventions for nutrition problems, 539
 iodine intake, 531–532
 low-iodine diet, 534–535, 536–538*b*, 538
 medullary thyroid carcinoma, 533*f*
 nutrition-related side effects and interventions, 129*b*
 papillary thyroid carcinoma, 533*f*
 radiotherapy and radioactive iodine therapy, 534–535, 538
 risk factors, 531–532
 sample PES statements, 540
 side effects related to low-iodine diet, 539
 surgery, 532
 treatment, 532, 534–535, 538
 types, 532, 533*f*
 United States statistics, 531*b*
 TNM. *See* tumor, (lymph) node, metastasis (TNM)
 tomatoes, prostate cancer, 519
 toremifene citrate (Fareston), hormonal agents, 178–179*b*
 total body irradiation, 184
 side effects of, 188*b*
 trace elements, parenteral nutrition, 236, 238*b*, 238–240
 trace minerals, hematopoietic cell transplantation, 312*b*
 traditional Chinese medicine (TCM), 89
 acupuncture, 90*b*, 95
 qigong, 90*b*
 resources, 102*b*
Trametes versicolor, 660
 trans-3,5,4'-trihydroxystilbene (resveratrol), 650
 transplantation. *See* hematopoietic cell transplantation
 trastuzumab (Herceptin), monoclonal antibodies, 172*b*
 tumor, (lymph) node, metastasis (TNM), classification system, 3, 3*b*, 283
 tumor grading system, American Joint Committee on Cancer, 4*b*
 tumorigenesis, 112
 tumor necrosis factor α , obesity and cancer, 43–44
 turkey tail mushroom, 660

U

UK Women's Cohort Study, 358
 United States Pharmacopeia, cannabis, 563
 United States statistics
 anal carcinoma, 407*t*
 cervical cancer, 499*t*
 cholangiocarcinoma, 407*t*
 colorectal cancer, 407*t*
 gallbladder cancer, 407*t*
 gastrointestinal cancers, 407*t*
 gynecologic cancers, 407*t*
 hepatocellular carcinoma, 407*t*
 neuroendocrine tumors of small bowel, 407*t*
 oral cavity cancer, 473*b*
 ovarian cancer, 499*t*
 pancreatic cancer, 436*b*
 pharynx cancer, 473*b*
 thyroid cancer, 531*b*
 uterine cancer, 499*t*
 vulvar cancer, 499*t*
 University of Texas MD Anderson, 455
 University of Virginia Health Systems, 222
 UpToDate website, 412
 urinary bladder cancer, nutrition-related side effects and interventions, 129*b*
 USDA. *See* US Department of Agriculture
 US Department of Agriculture, 112
 Pesticide Data Program, 24
 pesticide levels, 25
 US Dietary Guidelines for Americans, 500
 US Dietary Guidelines for Americans (2020–2025), 111, 112
 US Environmental Protection Agency, pesticides, 24
 US Food and Drug Administration, 112, 352, 600, 606
 cannabinoids, 564
 dietary supplements, 120*b*
 ginger, 632
 gynecologic cancer treatment, 504
 low-iodine diet, 535*b*
 oncolytic virus, 177

 pancreatic enzyme replacement products, 448, 449*t*
 washing produce, 25
 US Senate Committee on Labor and Human Resources, 115
 uterine cancer, 500. *See also* gynecologic cancers
 nutrition-related side effects and interventions, 129*b*
 risk and protective factors, 501*b*
 site and type, 503*f*
 treatment, 502
 United States statistics, 499*t*

V

vasomotor symptoms, breast cancer, 351
 Vegan Diet, 590–591
 vemurafenib (Zelmaraf), protein-targeted agent, 174*b*
 vinblastine (Velban), chemotherapy agent, 169*b*
 vinca alkaloids, chemotherapy, 169*b*
 vincristine (Oncovin), chemotherapy agent, 169*b*
 Viniyoga, yoga lineage, 97, 98*b*
 vinorelbine (Navelbine), chemotherapy agent, 169*b*
 Vinyasa, yoga lineage, 98*b*
 VITAL (VITamins And Lifestyle cohort) study, 630, 656
 vitamin(s)
 colorectal cancer, 425
 enteral nutrition, 232*b*
 parenteral nutrition, 236, 238–240, 239*b*, 244*b*
 patients with hepatic compromise, 416*b*
 requirements during hematopoietic cell transplantation, 312*b*
 vitamin A, pancreatic cancer survivors, 460*b*
 vitamin B-12
 deficiency after gastrectomy, 394*b*
 gastrointestinal cancers, 413*b*
 pancreatic cancer survivors, 460*b*

vitamin C, 18, 25
 vitamin D, 132
 breast cancer, 351–352
 breast cancer and supplements, 362–363
 dietary supplement, 22, 662
 hematologic malignancies, 288–290
 hematopoietic cell transplantation, 321
 osteoporosis, 292
 pancreatic cancer survivors, 460*b*
 pediatric cancer patients, 267–268, 268*t*
 prostate cancer, 519–520, 524*b*
 Recommended Dietary Allowance, 268*t*
 VITamin D and Omega-3 Trial (VITAL), 22
 vitamin E, 18, 25, 116, 132
 antioxidants, 119
 dietary supplement, 22
 pancreatic cancer survivors, 461*b*
 vomiting. *See also* nausea and vomiting
 chemotherapy-induced, 287, 352, 566
 prevalence in cancer patients, 547*t*
 vulvar cancer. *See also* gynecologic cancers
 United States statistics, 499*t*

W

Warburg, Otto, 335
Way to Health (Kushi Institute), 611
 WCRF. *See* World Cancer Research Fund (WCRF)
 weight gain
 adiposity and, 13, 15–16
 breast cancer treatment and, 353–354
 evaluating weight-related risk, 15–16
 foods promoting, 19, 19*b*
 weight loss
 breast cancer risk and, 359–360

 cancer risk and intentional, 39
 esophageal cancer, 379
 lung cancer, 492
 prevalence in cancer patients, 547*t*
 weight management
 breast cancer risk and, 358–359
 cancer survivors, 47, 48–49*b*
 medical nutrition therapy (MNT), 133, 135
 weight method, hydration, 78
 Weight Watchers (WW), 140–141*t*, 360
 Weir formula, 81
 WHEL. *See* Women's Healthy Eating and Living (WHEL)
 Wilms tumor
 distribution of childhood cancer, 251*f*
 nutrition side effects, 257
 survival percentage in children, 252*f*
 WINS. *See* Women's Intervention Nutrition Study (WINS)
 women, cancer types common in US, 1*t*
 Women's Health Initiative, 117, 146, 351
 Women's Health Initiative Observational Study, 644
 Women's Healthy Eating and Living, breast cancer, 355, 356
 Women's Healthy Eating and Living (WHEL), 144–145*t*, 146
 Women's Intervention Nutrition Study (WINS), 144–145*t*, 146
 World Bank, functional foods, 115*b*
 World Cancer Research Fund (WCRF), 13, 111
 alcoholic beverages, 21
 animal foods, 20
 cancer risk and body fatness, 37, 38*f*
 cancer survivors, 23–24, 26
 cancer survivorship, 149*b*
 dietary supplements, 22
 physical activity, 40
 predominantly plant-based diet, 17, 18*b*
 prevention recommendations, 14–15*b*
 red and processed meats, 19

World Cancer Research Fund/
 American Institute for
 Cancer Research (WCRF/
 AICR), Cancer Prevention
 Recommendations, 584–585
 World Cancer Research Fund
 International, 135, 279
 World Health Organization, 262,
 331, 491
 World Health Research Fund,
 physical activity guidelines and
 cancer, 42*b*

X

xerostomia
 considerations, 215*b*
 definition, 215*b*
 interventions, 215*b*
 pharmacotherapy, 215*b*
 prevalence in cancer patients, 547*t*
 severity grades, 215*b*

Y

Yin Yoga, 99*b*
 yoga, 89
 lineages, 98–99*b*
 mind-body intervention, 90*b*,
 97, 99–100
 resources, 102*b*
 Yoga for Cancer Survivors, 97
 Yoga in America study, 97
 Yoga nidra, 99*b*
 Yoga of Awareness, 97
 Yoga therapy, 99*b*
 Yoga Thrive, 97
 Yun Zhi (*Coriolus versicolor*,
Trametes versicolor, *Polyporus*
versicolor), 660

Z

zinc, pancreatic cancer survivors,
 461*b*
Zingiber officinale (ginger), 632
 Zink, Paulie, 99*b*